Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
06/2012 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions June invention type 06/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
06/28/2012 > 173 patent applications in 122 patent subcategories. invention type

20120165243 - Use of dietary fibres against muscle wasting: A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides,... Agent: N. V. Nutricia

20120165244 - Methods for binding lewis y antigen: The present invention relates to a method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues.... Agent:

20120165245 - Angiogenically effective unit dose of fgf and method of administering: The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically... Agent: Novartis Vaccines And Diagnostics, Inc.

20120165246 - Method of diagnosis of infection by mycobacteria and reagents therefor: The present invention provides a method of specifically detecting the presence of one or more Mycobacteria of the M. tuberculosis complex, said method comprising detecting ilvC nucleic acid of one or more Mycobacteria of the M. tuberculosis complex in a sample under conditions that do not detect ilvC nucleic acid... Agent: Tyrian Diagnostics Limited

20120165247 - Use of a composition for treatment and/or prophylaxis of plants and relative composition: A method of using a beef extract or a protein hydrolisate or a mixture of beef extract and protein hydrolisate, as active substance, for treatment and/or prophylaxis of plants against the action of pathogens is described. A composition including a beef extract or a protein hydrolisate or a mixture of... Agent:

20120165250 - Active cores of peptide triazole hiv-1 entry inhibitors: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-I entry inhibitor candidate.... Agent: Philadelphia Health & Education Corporation D/b/a Drexel University College Of Medicine

20120165248 - Glutathione derivatives and their uses for the treatment of viral diseases: Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus.... Agent: First S.r.l.

20120165249 - Stabilized therapeutic small helical antiviral peptides: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.... Agent:

20120165251 - Diabetes therapy: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.... Agent: Boehringer Ingelheim International Gmbh

20120165252 - Method of regulating glucose metabolism, and reagents related thereto: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism... Agent: New England Medical Center Hospitals, Inc.

20120165253 - Pharmaceutical composition for inhibiting peritoneal dissemination: A pharmaceutical composition for treating or preventing peritoneal dissemination is provided. The pharmaceutical composition includes an effective dose of connective tissue growth factor (CTGF) and an acceptable receptor thereof.... Agent:

20120165254 - Sulphated hyaluronic acid for treating degenerative osteoarthritis: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.... Agent: Fidia Farmaceutic S.p.a.

20120165255 - Therapeutic agent and therapeutic method for periodontal diseases and pulpal diseases: i

20120165256 - Use of erythropoietin and substances increasing and/or prolonging the activation and/or stimulation of erythropoietin receptors for treating and/or preventing schizophrenia and related psychoses: Method for treatment and/or prophylaxis of schizophrenia and related psychoses of a human being, erythropoietin being administered to the human being.... Agent:

20120165257 - Compositions and methods for treating joints: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both... Agent: Depuy Mitek, Inc.

20120165258 - Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets: Provided herein are methods and compositions, including pharmaceutical compositions, for treating thrombosis, vascular inflammation, and thrombocytopenia. The methods and compositions of the present invention are also useful for extending the useful storage shelf life of platelets.... Agent: Vasculogics, Inc.

20120165259 - Agent for ameliorating blood-brain barrier disorders: The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin α, or a protein or polypeptide possessing the same function as... Agent: Nagasaki University

20120165260 - Crystalline ezatiostat hydrochloride ansolvate: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.... Agent: Telik, Inc.

20120165261 - Alpha-1-antitrypsin compositions: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The... Agent: Csl Behring LLC

20120165262 - Compositions and methods for the treatment of disorders involving epithelial cell apoptosis: The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.... Agent:

20120165263 - Bone regeneration agent comprising gelatin: It is an object of the present invention to provide a bone regeneration agent and a bone supplementation formulation, in which a supplementation material itself is capable of promoting bone regeneration. The present invention provides a bone regeneration agent which comprises a gelatin having an amino acid sequence derived from... Agent: Fujifilm Corporation

20120165264 - Degradation-stabilised, biocompatible collagen matrices: The present invention relates to degradation-stabilised, biocompatible collagen matrices which are distinguished in particular by the fact that they contain soluble collagen and peptide constituents, to processes for the preparation of such collagen matrices, which processes include in particular chemical crosslinking with an epoxy-functional crosslinking agent, and to the use... Agent: Dr. Suwelack Skin & Health Care Ag

20120165265 - Calcium signaling modulators involving stim and orai proteins: The present invention provides compositions and methods for investigating the structural basis of the activation process of CRAC channels, which are essential for T-lymphocyte activation and adaptive immunity. The invention also provides compositions and methods to design, identify and evaluate agents that modulate calcium signaling by regulating the interaction between... Agent:

20120165266 - Method for preparing gintonin, which is a novel glycolipoproetin from panax ginseng, and gintonin, which is a novel glycolipoprotein, prepared by the method: Disclosed are the novel glycolipoprotein gintonin isolated and identified from ginseng, a method for preparing the same, and uses thereof. Gintonin causes a transient increase in intracellular free Ca2+ level, which in turn activates endogenous Ca2+-activated chloride channel to elevate intracellular calcium levels. Therefore, the novel glycolipoproteins are useful in... Agent:

20120165267 - Apo-2 ligand/trail variants and uses thereof: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.... Agent: Genentech, Inc.

20120165268 - P53 fusion proteins and methods of making and using thereof: Biologically active tetrameric p53 proteins and p53 fusion proteins are provided. These proteins may be generated and refolded into tetrameric form using denatured proteins produced from E. coli. Therapeutic uses of p53 proteins and p53 fusion proteins are also provided.... Agent: Proteom Tech, Inc.

20120165269 - Tumor cell-killing peptides: The present invention provides a tumor cell-killing peptide and a pharmaceutical composition for treating a cancer. The tumor cell-killing peptide of the present invention selectively homes into tumor cells so that it can induce the death of tumor cells effectively while minimizing the harming of normal cell.... Agent: Industry-academic Cooperation Foundation Chosun University

20120165270 - Inhibition of hair follicle growth by the wnt inhibitor dkk1: The invention provides methods of inhibiting hair growth in a post-natal subject by contacting a matured hair follicle cell with a DKK polypeptide. The inhibitory mechanism induced by a DKK polypeptide results in a reversible, transient inhibition of hair growth.... Agent:

20120165273 - Eye drops: An eyedrop containing a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg (“SSSR”), or a pharmacologically acceptable salt thereof; and a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 (“FGLM”), or a pharmacologically acceptable salt thereof. The concentration ratio between SSSR or a pharmacologically acceptable salt thereof and... Agent:

20120165271 - Methods of treating retinitis pigmentosa: The present invention relates to methods of treating retinitis pigmentosa using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa.... Agent:

20120165272 - Tear substitutes: The invention features ophthalmic formulations of mucin polypeptides to treat or prevent dry eye.... Agent: Recopharma Ab

20120165274 - Three-dimensional structures of tall-1 and its cognate receptors and modified proteins and methods related thereto: Disclosed are TALL-1 and TALL-1 receptor protein homologues (agonists and antagonists) designed based on the three-dimensional structure of sTALL-1, eBCMA and eBAFF-R; agonist homologues of APRIL; methods of using wild-type APRIL to inhibit the activity of TALL-1; compositions comprising such homologues, nucleic acid molecules encoding such homologues, and therapeutic methods... Agent:

20120165275 - Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules: Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.... Agent: Affymax, Inc.

20120165276 - Quaternary alkyl ammonium bacterial efflux pump inhibitors and therapeutic uses thereof: Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an... Agent: Mpex Pharmaceuticals, Inc.

20120165277 - Novel galactoside inhibitors of galectins: Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The... Agent: Forskarpatent I Syd Ab

20120165278 - Pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same: The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20120165279 - Pharmaceutical composition and method for preventing or treating hepatitis c: A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above.... Agent: Industrial Technology Research Institute

20120165280 - Method for improving blood flow using stilbenoid derivatives: The present invention generally provides methods for using stilbenoid derivatives to improve blood flow and microcirculation.... Agent: The Board Of Trustees Of The University Of Arkansas

20120165281 - Stilbenoid derivatives and their uses: The present invention generally provides stilbenoid derivatives and methods for using stilbenoid derivatives to modulate the activity of cannabinoid receptors or scavenge reactive nitrogen species.... Agent: The Board Of Trustees Of The University Of Arkansa

20120165282 - Antibacterial aminoglycoside analogs: e

20120165283 - Novel aminoglycoside antibiotics: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or... Agent:

20120165389 - Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndrome: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length... Agent:

20120165395 - Bruton's tyrosine kinase as anti-cancer drug target: Receptor protein tyrosine kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of the tyrosine... Agent: The Research Foundation Of State University Of New York

20120165397 - Chemical modification of short small hairpin rnas for inhibition of gene expression: Aspects of the present invention include the production and use of chemically modified RNAi agents (e.g., shRNAs) in gene silencing applications. The chemically modified RNAi agents disclosed herein have reduced immunostimulatory activity, increased serum stability, or both, as compared to a corresponding RNAi agent not having the chemical modification. Compositions... Agent:

20120165390 - Compositions and methods for therapy and diagnosis of cancer: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating... Agent: Ganymed Pharmaceuticals Ag

20120165388 - Fatty acid binding proteins as drug targets for endocannabinoids: The invention provides a method of modulating the level of an endocannabinoid in a subject in need thereof comprising administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The invention also provides a method of identifying an... Agent: The Research Foundation Of State University Of New York

20120165387 - General composition framework for ligand-controlled rna regulatory systems: The invention provides an improved design for the construction of extensible nucleic acid-based, ligand-controlled regulatory systems, and the nucleic acid regulatory systems resulting therefrom. The invention contemplates improving the design of the switches (ligand-controlled regulatory systems) through the design of an information transmission domain (ITD). The improved ITD eliminates free-floating... Agent:

20120165392 - Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure: The present invention relates to the identification of miRNAs that are involved in heart failure and the process of post-myocardial infarction remodeling in heart tissue. Modulation of these identified miRNAs as a treatment for myocardial infarction, cardiac remodelling, and heart failure is described.... Agent: Board Of Regents, The University Of Texas System

20120165396 - Modulation of exportin 5 expression: Compounds, compositions and methods are provided for modulating the expression of exportin 5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding exportin 5. Methods of using these compounds for modulation of exportin 5 expression and for diagnosis and treatment of diseases and conditions associated with expression of exportin 5... Agent: Isis Pharmaceuticals Inc.

20120165393 - Peptide-based in vivo sirna delivery system: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible... Agent: Arrowhead Madison Inc.

20120165398 - Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors: Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors.... Agent: Technion Research & Development Foundation Ltd.

20120165399 - Snornai-small nucleolar rna degradation by rna interference in trypanosomatids: Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as... Agent: Bar-ilan University

20120165394 - Spinal muscular atrophy (sma) treatment via targeting of smn2 splice site inhibitory sequences: The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the... Agent: University Of Massachusetts

20120165391 - Use of inhibitors of zdhhc2 activity for modulation of adipogenesis: The present invention concerns Zdhhc2, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Zdhhc2 activity in adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Zdhhc2 activity as well as screening test for identification of... Agent: Sanofi

20120165401 - Aptamer for chymase, and use thereof: Provided are an aptamer bound to chymase to inhibit activity of chymase; an aptamer containing a nucleotide sequence represented by X1GAUAGAN1N2UAAX2 wherein X1 and X2 are the same or different and each is A or G, and N1 and N2 are the same or different and each is A, G,... Agent: Ribomic Inc.

20120165400 - Gene repair involving in vivo excision of targeting dna: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.... Agent: The Institute Pasteur

20120165284 - Pharmaceutical composition comprising a3 adenosine receptor agonist (ib-meca/cf-101) for treatment of psoriasis: The present invention is based on the clinical finding that twice daily administrations of 2 mg of 1-[N6-(3-iodobenzyl)-adenin-9-yl]-β-D-ribofuronamide (IB-MECA) (total daily administration of 4 mg) to subjects having moderate to severe psoriasis, was significantly more effective in treatment of the psoriatic plaques than treatment of psoriasis at two administration doses... Agent: Can-fite Biopharma Ltd.

20120165285 - Combined preparation for use as a medicament: A combined preparation comprising an A2A adenosine receptor agonist and a calcium channel blocker is described. The effect of the A2A adenosine receptor agonist is enhanced in the presence of the calcium channel blocker. Methods for treatment of pathological conditions using the combined preparation are described.... Agent:

20120165286 - Cyclic nucleotide analogs: Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.... Agent: Alios Biopharma, Inc.

20120165287 - Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect: The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent.... Agent: Wilex Ag

20120165288 - Azapeptide derivatives: This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier,... Agent:

20120165291 - Acidic composition for external use and agent for accelerating infiltration of cosmetic preparation, hair-growing agent, and preparation for external use each containing the composition into skin or the like: An acidic composition for external use which contains an acidic polysaccharide and water as essential ingredients, and an agent for accelerating the penetration into skin or the like of a cosmetic preparation, hair-growing agent or preparation for external use, each containing the composition. The composition is easy to manufacture, and... Agent: Neochemir Inc.

20120165290 - Glucooligosaccharides comprising (alpha 1->4) and (alpha 1->6) glycosidic bonds, use thereof, and methods for providing them: The invention relates to the field of poly- and oligosaccharides and their nutritional effects. In particular, it relates to the application of α-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one... Agent:

20120165289 - Treatment: The invention provides composition comprising a therapeutically effective amount of a soluble fibre derivable from fruit of the Musa spp that may be used as a medicament for preventing or treating antibiotic associated diarrhoea (AAD). The soluble fibre is derivable from an aqueous solution decantable from homogenised fruit, and may... Agent: Provexis (ibd) Limited

20120165292 - Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-(is)-(3-ethoxy-4methoxy-phenyl)-2-methanesulfonyl-ethyl}-3-oxo-2.3-dihydro-1h-isoindol-4-yl}-amide: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of... Agent: Celgene Corporation

20120165294 - 4,5-dihydro-oxazol-2yl derivatives: R1, R2, X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine... Agent:

20120165293 - Synthesis of prostanoids: The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of... Agent:

20120165295 - Compounds, compositions and methods for treating ocular conditions: The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.... Agent: Chimerix, Inc.

20120165296 - Bisphosphonate-prodrugs: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.... Agent: Ktb Tumorforschungsgesellschaft Mbh

20120165297 - Synergistic combination of a glyphosate compound and dmits: A synergistic antimicrobial composition containing a glyphosate compound and diiodomethyl-p-tolylsulfone is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial... Agent:

20120165298 - Sulfonamide compounds: s

20120165299 - Combination medicament: A medicament for treating inflammation of human or animal body tissues contains a steroid, typically a corticosteroid, in combination with a non-steroidal anti-inflammatory drug (NSAID), typically a cyclooxygenase (COX-1 or COX-2) inhibitor. The medicament is of a particular effectiveness in treating inflammation of and around the eyes, whether caused by... Agent:

20120165301 - Benzodiazepine compositions for treating epidermal hyperplasia and related disorders: The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog. The pharmaceutical compositions are useful for treating medical disorders, such as epidermal... Agent: The Regents Of The University Of Michigan

20120165300 - Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3: Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent:

20120165302 - Antifungal formulations: A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. The composition... Agent:

20120165304 - 6,7,8,9-tetrahydro-5h-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them: The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which... Agent: Boehringer Ingelheim International Gmbh

20120165307 - Azaindoles useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120165306 - Pyrazinylpyridines useful for the treatment of proliferative diseases: e

20120165305 - Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3: The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases.... Agent:

20120165308 - Use of parthenolide derivatives as antileukemic and cytotoxic agents: e

20120165303 - Triazolyl phenyl benzenesulfonamides: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of... Agent: Chemocentryx, Inc.

20120165311 - 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors: Thieno[2,3-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.... Agent: Nerviano Medical Sciences S.r.l.

20120165310 - Ether derivatives of bicyclic heteroaryls: i

20120165309 - Hetero ring derivative: It was found that a 3-substituted triazine or 3-substituted pyrimidine derivative exhibits a PI3Kδ-selective inhibitory action, and/or an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action (including an activation inhibitory action), and can be an agent for preventing or treating rejection in the transplantation of various organs,... Agent: Astellas Pharma Inc.

20120165312 - Fused heterocyclic compound and use thereof: wherein ring A is a 5- or 6-membered aromatic heterocycle optionally having substituent(s), and ring B is a 7- to 9-membered ring optionally having substituent(s) other than an oxo group wherein the combination of m and n (m,n) is (1,2), (2,1), (2,2), (3,1), (3,2) or (4,1), or a salt thereof... Agent:

20120165313 - Pyrimidine compounds, compositions and methods of use: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK... Agent: Genentech, Inc.

20120165314 - Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis: This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.... Agent: Bayer Healthcare LLC

20120165315 - Meptazinol carbamate prodrug salts: The present invention relates to salts of meptazinol carbamate prodrugs, and to their synthesis and use.... Agent:

20120165317 - 8-substituted benzoazepines as toll-like receptor modulators: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency.... Agent: Array Biopharma Inc.

20120165316 - Substituted hydroxamic acids and uses thereof: wherein R1, R2, X, p, q, m, n, and Ring C have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or... Agent: Millennium Pharmaceuticals, Inc.

20120165318 - Heterocyclic compounds for the inhibition of pask: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.... Agent: Bioenergenix

20120165319 - Inhibitors of interleukin-1 beta converting enzyme: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly... Agent: Vertex Pharmaceuticals Incorporated

20120165320 - Novel azabicyclohexanes: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms,... Agent: Panacea Biotec Ltd.

20120165321 - Quinoline derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent:

20120165322 - Rho kinase inhibitors: v

20120165323 - Method for improving the dissolution profile of a biologically active material: The present invention relates to a method for improving the dissolution profile of a biologically active material comprising the steps of dry milling a solid biologically active material and a millable grinding matrix in a mill comprising a plurality of milling bodies, for a time period sufficient to produce particles... Agent:

20120165324 - Therapeutic compositions and related methods of use: Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.... Agent:

20120165325 - Stable forms of n-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide: Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound.... Agent: H. Lundbeck A/s

20120165326 - Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro benzothiazoles and 5-fluoro benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors: The invention relates to novel products of the formula (I) where: (II) is a single or double bond; F is a fluorine atom, Ra is H, HaI, alkoxy, O-cycloalkyl, —O— heterocycloalkyl; —NH-heterocycloalkyl, heteroaryl, phenyl, NHCOalk NHCOcycloalk or NR1 R2; X is S, SO or SO2, A is NH or S;... Agent: Sanofi

20120165327 - Spiropiperidines for use as tryptase inhibitors: e

20120165329 - Compounds and methods for kinase modulation, and indications therefor: Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one of Fms protein kinase or Kit protein kinase.... Agent: Plexxikon Inc

20120165328 - Inhibitors of b lymphocyte kinase: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.... Agent: Pharmacyclics, Inc.

20120165330 - Quinazolinone and related analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtris Pharmaceuticals, Inc.

20120165331 - Di/tri-aza-spiro-c9-c11alkanes: o

20120165332 - Sulfonamides and sulfamides as zap-70 inhibitors: wherein R1 to R6 and T0 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the... Agent: Cellzome Limited

20120165333 - C-met protein kinase inhibitors: The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120165334 - Indole/benzimidazole compounds as mtor kinase inhibitors: The present invention provides compounds that are kinase inhibitors, specifically PIK kinase inhibitors, more specifically, mTOR inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PIK kinase inhibitors, more specifically, mTOR such as cancer. Also provided are pharmaceutical compositions containing such compounds and... Agent: Amgen Inc.

20120165335 - Cdk inhibitors: The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer.... Agent: Curis, Inc.

20120165336 - Color change time indicator for packaging system: Disclosed in certain embodiments is a pharmaceutical packaging system comprising: a receptacle comprising an openable seal for accessing the interior of the receptacle; a pharmaceutical dosage form contained in the receptacle; and an activatable color-changing material, wherein upon activation, the material exhibits a visually discernible color change upon the lapsing... Agent: Purdue Pharma L.p.

20120165337 - Tetrahydroquinoxaline urea derivatives, preparation thereof, and therapeutic use thereof: ile="US20120165337A1-20120628-P00002.TIF" alt="custom-character" img-content="character" img-format="tif"/>lkyl group, or lkyl-phenyl; R6 and R7, identical or different, are each a hydrogen atom, an alkyl group, alkoxy, or an alkyl-phenyl group; and R8 is a hydrogen atom or an O2-alkyl group, or a group of formula -Het, where B can be absent or be a... Agent: Sanofi

20120165339 - Cyclopropane derivatives: e

20120165338 - New biaryl amide derivatives:

20120165340 - Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis: Indicators that can guide clinical decisions in cancer, particularly posttranslational modification of proteins which result in altered prognosis and differential sensitivity to targeted cancer therapy, are provided. In particular, monitoring of phosphorylation of PTEN may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome. Modulation of... Agent: Ludwing Institute For Cancer Research Ltd.

20120165341 - Therapeutic agent for senile dementia: d

20120165342 - Methods of reducing risk of infection from pathogens: Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed... Agent: Parion Sciences, Inc.

20120165343 - Glucagon receptor modulators: or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions... Agent: Pfizer Inc.

20120165346 - Compounds and their use as bace inhibitors: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage,... Agent: Astrazeneca Ab

20120165347 - Compounds and their use as bace inhibitors: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders... Agent: Astrazeneca Ab

20120165344 - Compounds for the treatment of hepatitis c: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Agent: Bristol-myers Squibb Company

20120165345 - Heterocyclic compounds as pesticides: The present application relates to novel heterocyclic compounds, to the use thereof for controlling animal pests, which include arthropods and especially insects, and to processes for preparing the novel compounds.... Agent: Bayer Cropscience Ag

20120165348 - Novel compounds: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.... Agent: Astrazeneca Ab

20120165349 - Phenyl-substituted pyrazolopyrimidines: The invention relates to novel phenyl-substituted pyrazolopyrimidines, process for their preparation, and their use for producing medicaments for improving perception, concentration, learning and/or memory.... Agent: Boehringer Ingelheim International Gmbh

20120165350 - Process for preparing an a2a-adenosine receptor agonist and its polymorphs: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.... Agent: Gilead Sciences, Inc.

20120165351 - Quinazoline derivatives: or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a... Agent: Astrazeneca Ab

20120165352 - 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof: 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20120165353 - Novel phenylpyridine derivative and medicinal agent comprising same: Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the... Agent: Kowa Company, Ltd.

20120165355 - Methods and compositions for treating cancers: This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit.... Agent:

20120165354 - Treatment method: The present invention relates to methods of treating age-related macular degeneration in a patient by administration of pazopanib or pharmaceutically acceptable salts or solvates thereof.... Agent: Glaxo Wellcome Manufacturing Pte Ltd.

20120165356 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Adolor Corporation

20120165357 - Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders: The invention pertains to topical pharmaceutical formulations of berberine and its biologically equivalent analogues, such as palmatine and coptisine, for the treatment of rosacea and other red face-related skin disorders. The topical pharmaceutical formulations of this invention contain purified berberine as the primary active drug ingredient at concentrations higher than... Agent: Derman Biomedicine Co. Ltd.

20120165360 - Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor... Agent: Theravance, Inc.

20120165358 - Controlled release formulations of opioid and nonopioid analgesics: Sustained release dosage forms for twice daily oral dosing to a human patient for providing relief from pain are provided. The sustained release dosage form comprises an immediate release component and a sustained release component, wherein the immediate release component and the sustained release component collectively contain a therapeutically effective... Agent:

20120165361 - Drug coating providing high drug loading and methods for providing the same: The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or... Agent:

20120165359 - Opioid agonist/antagonist combinations: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective... Agent: Purdue Pharma L.p.

20120165362 - Androgen receptor modulator compounds and methods: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors, and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.... Agent:

20120165363 - Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders: Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.... Agent: Avanir Pharmaceuticals, Inc.

20120165364 - Novel forms of tiotropium bromide and processes for preparation thereof: This invention relates to novel crystalline forms of tiotropium bromide, processes for preparing them, and their use in pharmaceutical formulations.... Agent: Sicor Inc.

20120165365 - Compositions and methods for treating cancer: The present invention embraces bis-acridine and bis-quinoline intercalators having a bis(4-aminophenyl)ether tether, and diglycolate salts thereof, for selectively decreasing colon cancer and glial cell proliferation and preventing or treating colon cancers and gliomas.... Agent: Trustees Of Dartmouth College

20120165366 - Compounds and uses thereof: N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, N-[3-(4-ethynyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods... Agent: Plexxikon Inc.

20120165367 - Azaindazoles useful as inhibitors of kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20120165368 - Pyrazolopyridine kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent:

20120165369 - 3-substituted quinolinium and 7h-indolo[2,3-c]quinolinium salts as new antiinfectives: e

20120165370 - Quinoline derivatives as anti-cancer agents: Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas:... Agent:

20120165372 - Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide: Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are described herein, including crystalline forms thereof.... Agent: Vertex Pharmaceuticals Incorporated

20120165371 - Spiro substituted compounds as angiogenesis inhibitors: The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the... Agent: Advenchen Laboratories, LLC

20120165373 - Method of treating skin with microrna modulators: Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that suppress or down-regulate microRNA expression in dermal fibroblast, resulting in enhanced production of collagen, elastin and/or fibrillin in the skin. Also provided are methods for screening for activity against specific microRNAs and the... Agent: Avon Products, Inc.

20120165374 - Agents for controlling plant pests: t

20120165375 - Urea glucokinase activators: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a... Agent: Novo Nordisk A/s

20120165376 - Stabilized microbicidal composition: A microbicidal composition having at least four components. The first component is 2-25 wt % of 2,2-dibromo-3-nitrilopropionamide. The second component is 2-30 wt % water. The third component is 5-30 wt % of an aliphatic compound having 2-6 hydroxyl groups. The fourth component is 20-70 wt % of a glycol... Agent:

20120165377 - Agent for reducing visceral fat weight: wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or... Agent: Kowa Co., Ltd.

20120165378 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of... Agent: Vertex Pharmaceuticals Incorporated

20120165379 - Allantoin-containing skin cream: An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about... Agent: Alwyn Company Inc.

20120165380 - Methods of treating alpha adrenergic mediated conditions: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.... Agent: Allergan, Inc.

20120165381 - Dual-acting imidazole antihypertensive agents: wherein: Ar, r, R2-3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for... Agent: Theravance, Inc.

20120165382 - Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response: e

20120165383 - Inflammatory eye disease: The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors.... Agent: Massachusetts Eye & Ear Infirmary

20120165384 - Inhibition of histone acetyltransferases by ctk7a and methods thereof: The present disclosure relates to a method for inhibiting histone acetyltransferases by derivative of curcumin, particularly CTK7A. The present disclosure also relates to identification of induction of autoacetylation of p300 and its inhibition by CTK7A. The disclosure also relates to induction of NPM1 and GAPDH overexpression and corresponding hyperacetylation of... Agent: Jawaharlal Nehru Centre For Advanced Scientific Research

20120165385 - Novel compounds and compositions thereof: The invention relates to novel compounds containing a carboxylic acid head group. The invention further provides compositions containing the novel compounds, a particulate solid and an organic medium or water.... Agent: Lubrizol Limited

20120165386 - Stable oral pharmaceutial composition of atorvastatin: The present invention relates to a stable oral pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent, wherein the buffering capacity of the composition is between 2 to 5.... Agent: Ranbaxy Laboratories Limited

20120165402 - Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as... Agent: Gw Pharma Limited

20120165403 - Methods of inhibiting the activity of hsp90 and/or aryl hydrocarbon receptor: The present invention relates to a method of screening compounds for binding to hsp90 by exposing a compound to hsp90 or a polypeptide fragment thereof containing amino acid residues 538-728 of the full length protein and determining whether the compound binds to hsp90 of the polypeptide fragment thereof. Also disclosed... Agent: University Of Rochester

20120165405 - Anaplerotic therapy of huntington disease and other polyglutamine diseases: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.... Agent: Inserm (institut National De La Sante Et De La Recherche Medicale)

20120165404 - Treatment of neurodegeneration and neuroinflammation: Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroinflammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.... Agent: Biogen Idec Ma Inc.

20120165406 - Bis-trifluoromethyl honokiol analogs and their use in treating cancers: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are hexafluoro-honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative hexafluoro-honokiol analogs include hexafluoro-honokiol, analogs in which one or... Agent: Jack L. Arbiser

20120165407 - Strategy for on-site in situ generation of oxidizing compounds and application of the oxidizing compound for microbial control: The invention provides a method of controlling biological fouling of water containing items. The method involves combining at least two reactants, a peroxygen source and an acyl group donor to form peracetic acid. Because the peracetic acid can be made in situ, the entire sum of its short lifespan can... Agent:

20120165408 - Oral composition for alleviating rough skin: Provided is a stable and safe oral composition that acts on the barrier function of the skin for alleviating and/or preventing rough skin. An oral composition for alleviating rough skin and an oral composition for preventing rough skin are provided, the compositions containing at least one compound selected from the... Agent: Shiseido Company, Ltd.

20120165409 - Wrinkle-improving agent: A wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives, and salts thereof have... Agent: Shiseido Company, Ltd.

20120165410 - Production of encapsulated nanoparticles at high volume fractions: The present invention relates to methods for producing particles of a biologically active material using dry milling processes as well as compositions comprising such materials, medicaments produced using said biologically active materials in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically... Agent:

20120165411 - Method for treating pancreatitis: Gemcabene, a carboxyalkylether, is effective in the treatment and prevention of pancreatitis in subjects. The compound can be administered in an effective dose as the free acid, a pharmaceutically acceptable salt, or an ester or pro-drug that is hydrolyzed or otherwise metabolized in situ to gemcabene as the free acid... Agent:

20120165412 - Use of resveratrol or another hydroxylated stilbene for preserving cognitive functioning: The present invention relates to the use of an hydroxylated stilbene, in particular resveratrol, in the manufacture of a neutraceutical composition for increasing the microvascular plasticity and/or microvessel density, and/or decreasing the microvessel abnormalities in the brain, in particular in the hippocampus of a mammal, in particular for the treatment... Agent: N.v. Nutricia

20120165413 - Disintegrating particle composition and orally rapidly disintegrating tablet: Disclosed is an orally rapidly disintegrating tablet which has a good texture and taste in the oral cavity, such a sufficient hardness as not giving any worry of being chipped or dusted during production or transportation and good disintegrating properties in the oral cavity. The orally rapidly disintegrating tablet, which... Agent:

20120165414 - Terminal unsaturated, glycidol-based macromonomers, polymers obtainable therefrom, preparation and use: s

20120165415 - Emulsion system derives from engkabang fat esters: An isotropic or homogeneous emulsion system comprises an oil phase including fat esters of illipe fat and a solubilizer; a non-ionic surfactants; and deionized water; characterized in that the solubilizer is a mixture of polyethyleneglycol-40 hydrogenated castor oil, polysorbate 20 and octoxynol-12.... Agent:

  
06/21/2012 > 183 patent applications in 141 patent subcategories. invention type

20120157371 - High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier... Agent:

20120157373 - Antimicrobial compounds having protective or therapeutic leaving groups: Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving... Agent: Medtronic, Inc.

20120157372 - Human milk peptides: The present invention provides for novel peptides derived from human milk In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk... Agent:

20120157374 - Nodule specific medicago peptides having antimicrobial activity and pharmaceutical compositions containging the same: The present invention relates to the use of at least one peptide originated from Medicago truncatula nodules, including the SEQ IDs NO: 1-463 or at least one peptide having a sequence derived from the SEQ IDs NO: 1-463 by deletion of about 9 to about 44 contiguous amino acids, from... Agent: Centre National De La Recherche Scientifique

20120157375 - Identification of inhibitors of a bacterial stress response: A system, a composition, a method and a kit for identifying anti-bacterial agents are provided. The invention described herein is useful in identifying inhibitors of any bacterial stress response. Moreover, the invention can be applied to any sRNA and its target, any transcription factor and its target, and any transcription... Agent:

20120157376 - Pharmacologically active antiviral peptides and methods of their use: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral... Agent: Wisconsin Alumni Research Foundation

20120157377 - Methods to enhance night vision and treatment of night blindness: The invention is for a safe and effective method of administering an opthalmological therapeutic agent for the treatment of night blindness and improving night vision, using insulin, and chlorin e6, preparations instilled into the conjunctival sac as ophthalmic drops. Night blindness and decreased night vision is associated with retinal diseases... Agent:

20120157378 - Methods and compositions for predicting a subject's susceptibility to and risk of developing type 2 diabetes: Aspects of the invention include methods of predicting a subject's susceptibility to developing type 2 diabetes. Embodiments of the methods include obtaining a sex hormone-binding globulin (SHBG) level value for the subject, e.g., by detecting a SHBG plasma concentration and/or a SHBG polymorphism phenotype, and predicting the subject's susceptibility to... Agent:

20120157379 - Gastric inhibitory peptide variants and their uses: Novel gastric inhibitory peptide (GIP) polypeptide compositions are provided. Human GIP alleles encode an extended peptide, referred to herein as GIP55S or GIP55G, which is resistant to serum degradation, relative to the known mature GIP peptide. GIP55S or GIP55G peptides find use where it is desirable to modulate insulin secretion.... Agent:

20120157380 - Pegylated human apoa-1 and process for production thereof: An isolated mono-pegylated apolipoproteinA-1, compositions comprising such, and methods of treating cardiovascular diseases using mono-pegylated apolipoproteinA-1 are provided as well as processes for making isolated mono-pegylated apolipoproteinA-1 and compositions containing such.... Agent:

20120157381 - Compositions and methods for cardiac tissue repair: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.... Agent: The University Of Vermont And State Agriculture College

20120157382 - Pharmaceutical glp-1 compositions having an improved release profile: This invention relates to sustained release liquid pharmaceutical compositions containing a peptide analogue of glucagon-like peptide-1 or salts thereof having an improved release profile. The invention also relates to methods for preparing such compositions.... Agent:

20120157383 - Neprilysin inhibitors: i

20120157384 - Mutants pf4 polypeptides exhibiting an increased anti-angiogenic activity: The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein.... Agent:

20120157385 - Cyclosporin conjugates: A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R1 and R1 represents hydrogen and the other represents methyl, R2 represents ethyl or isopropyl,... Agent: Ucl Business PLC

20120157386 - Neprilysin inhibitors: c

20120157387 - Orally bioavailable d-gamma-glutamyl-d-tryptophan: Provided are compounds which are prodrugs of D-gamma-glutamyl-D-tryptophan, methods of making the compounds and methods for using the compounds.... Agent: Apotex Technologies Inc.

20120157388 - External composition for skin: A moisturizing agent comprising one or more than one compound selected from the group consisting of lysyl-β-alanine represented by the following general formula (1) and a salt thereof:... Agent: Shiseido Company, Ltd.

20120157390 - Iap inhibitors: Smac mimetics that inhibit IAPs.... Agent: Tetralogic Pharmaceuticals Corporation

20120157389 - Peptides for treating cancer: The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX1X2X1 motif (SEQ ID NO: 1), wherein each X1 independently is M or Nle and X2 is any amino acid, pharmaceutical compositions comprising said peptide and use thereof for treating cancer.... Agent: Gene Signal International Sa

20120157391 - Proteoglycan-containing material: The present invention was made in view of an object to produce a novel proteoglycan-containing material, and find a novel use and/or a superior effect of the proteoglycan-containing material. The present invention provides a proteoglycan-containing material obtained from fish cartilage, wherein the proteoglycan-containing material comprises an acidic saccharide component having... Agent: Sunstar Inc.

20120157392 - Epilepsy treatment employing ketogenic compounds which arrest apoptosis: Method of treating a patient suffering from apoptosis of tissue by administering to the patient a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced which arrests the apoptosis.... Agent: Btg International Limited

20120157393 - Biopolymer, implant comprising it and uses thereof: The present invention relates to a biopolymer, bioactive and totally biocompatible, very fluid at ambient temperature, capable of gelling in a sudden manner at 37° C., forming a solid implant, structurally integral and continuous having high mechanical properties. The biopolymer comprises at least a bioactive domain capable of directing in... Agent: Universidad De Valladolid

20120157395 - Anti-inflammatory agent for oral application, and anti-inflammatory peptide for oral application: Disclosed are a composition having an anti-inflammatory function and a therapeutic method using the composition, both of which are effective for inflammatory diseases such as inflammatory bowel disease. Specifically disclosed are: an anti-inflammatory functional agent for oral application, which comprises a soybean peptide, wherein the soybean peptide contains fractions each... Agent:

20120157394 - Selective caspase inhibitors and uses thereof: The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I,... Agent: New World Laboratories, Inc.

20120157396 - Pyrazinamide for immunostimulation and the treatment of leishmaniases: e

20120157397 - Trimethylamine-containing compounds for diagnosis and prediction of disease: The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two... Agent:

20120157398 - Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity: Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include... Agent:

20120157399 - Bile acid recycling inhibitors for treatment of obesity and diabetes: Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.... Agent: Satiogen Pharmaceuticals, Inc.

20120157402 - Methods for treating brain tumors: Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.... Agent:

20120157400 - Methods for treating kaposi sarcoma: Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.... Agent:

20120157401 - Methods for treating neurofibromatosis: Methods for treating neurofibromatosis involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a single-agent therapy or in combination with one or more additional therapies to a human in need of such treatment.... Agent: Ptc Therapeutics, Inc.

20120157511 - 5' phosphate mimics: The present invention provides nucleosides and oligonucleotides comprising a 5′ phosphate mimics of formula (IVc) or (Vc). One aspect of the present invention relates to modified nucleosides and oligonucleotides comprising such dinucleotide of formula (Ia). Another aspect of the invention relates to a method of inhibiting the expression of a... Agent: Alnylam Pharmaceuticals, Inc.

20120157510 - Controlling the potential of primate neural stem cells by regulating pax6: A transcription factor both necessary and sufficient for human neuroectoderm specification, Pax6, as well as applications thereof, is disclosed.... Agent: Wisconsin Alumni Research Foundation

20120157509 - Galactose cluster-pharmacokinetic modulator targeting moiety for sirna: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery... Agent: Arrowhead Research Corporation

20120157512 - Preventing and curing beneficial insect diseases via plant transcribed molecules: Methods and compositions for transforming plants to express polynucleotides capable of gene silencing gene expression in pathogens of beneficial insets such as IAPV, Nosema species and Varroa mites, and methods for using the transgenic plants for reducing infection and susceptibility of bees to Colony Collapse Disorder are provided.... Agent: Monsanto Technology LLC

20120157508 - Targeting en2, pax2, and/or defb1 for treatment of prostate conditions: The present invention relates to methods and compositions for treating a prostate condition in a subject. The method comprises administering to the subject a subject effective amount of a pharmaceutical composition having a first agent that inhibits EN2 expression and/or EN2 activity and a second agent that inhibits PAX2 expression... Agent: Phigenix, Inc.

20120157507 - Usp47 inhibtors and methods to induce apoptosis: The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds... Agent: New York University

20120157514 - Oligomeric compounds and compositions for use in modulation of small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment... Agent: Regulus Therapeutics Inc.

20120157513 - Small peptide expression system in mammalian cells: The present invention is directed to a delivery vector for transferring a small peptide coding sequence to a cell for expression of the small peptide coding sequence within the cell. The delivery vector comprises a secretory signal sequence; a sequence encoding a carrier protein operatively associated with the secretory signal... Agent:

20120157403 - Bicyclic and tricyclic derivatives as thrombin receptor antagonists: represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R3, R10, R11, R32 and R33 are herein defined and the... Agent:

20120157404 - Antiviral compounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences, Inc.

20120157405 - Methods and compositions for the treatment of \"burning feet syndrome\": A composition for the treatment of “Burning Feet Syndrome” includes pantothenic acid or its analogs, or its derivatives, or its synonyms, alpha-lipoic acid or its analogs, or its derivatives, or its synonyms, and L-arginine or its analogs, or its derivatives, or its synonyms. The composition may also include at least... Agent:

20120157406 - Method of preventing diarrhoea: The present invention provides a method for the prevention of the incidence of and/or a reduction in the duration of acute diarrhoea, particularly in travellers, said method comprising orally administering an oligosaccharide composition, in particular a non-digestible oligosaccharide, to a mammal.... Agent:

20120157407 - Galactose-pronged polysaccharides in a formulation for antifibrotic therapies: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v)... Agent:

20120157408 - Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer: The present invention is related to a method of treating and preventing peptic ulcer and duodenal ulcer by administering hyaluronic acid composition with a binary mixture of hyaluronic acids having mainly different weight-average molecular weight and then different rheological, scaffold and degradation properties in aqueous solution. The resulted compositions have... Agent:

20120157409 - Appetite suppressant product and method: An appetite suppressant composition that is effective for the control of mammalian weight and methods of administration of the composition of the invention are provided. The composition is a cellulose product prepared with ethanol preferably with added sweetener, spice(s), salt and protein for oral administration to a patient.... Agent:

20120157410 - Compositions and treatments using pyridazine compounds and cholinesterase inhibitors: The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.... Agent: National Institute Of Health (nih), U.s. Department Of Health And Human Services (dhss),

20120157411 - 2-amino-4-arylthiazole compounds as trpai antagonists: The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described... Agent: Glenmark Pharmaceuticals, S.a.

20120157412 - Substituted pyrimidinyl oxime kinase inhibitors: e

20120157413 - Phosphorous derivatives as chemokine receptor modulators: The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.... Agent: Allergan, Inc.

20120157414 - Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.... Agent: Jenrin Discovery

20120157415 - New crystalline form of pemirolast: There is provided a hemihydrate form of the sodium salt of pemirolast.... Agent: Cardoz Ab

20120157416 - xylitol containing comestible product: The present invention relates to a process for preparing a comestible product comprising xylitol said method comprising: (a) subjecting a composition comprising xylitol in an amount ranging from about 60% to about 100% by weight to extrusion treatment inside an extrusion apparatus under conditions sufficient to form and maintain the... Agent: Hershey Foods Corporation

20120157417 - Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease: In one aspect, the present invention relates to amino-salicylic—aminophenylpropionic compounds for the use in the treatment of the inflammatory component of the celiac disease. These compounds act by blocking the cytokines released in the celiac disease and are specifically useful in the treatment of cases refractory to the diet, in... Agent:

20120157418 - 2-methylene-19-nor-vitamin d analogs and their uses: This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D3 and (20R)-25-hydroxy-2-methylene-19-nor-vitamin D3, as well as pharmaceutical uses therefor. These compounds exhibit relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent... Agent: Wisconsin Alumni Research Foundation

20120157419 - Methods and compositions for treating alzheimer's disease: The present invention relates to methods for treatment, prevention, and inhibition of progression of Alzheimer's disease, and other brain diseases characterized by amyloid plaque deposits, comprising the administration to a subject a bile acid fatty acid conjugates or bile salt fatty acid conjugate (FABAC).... Agent:

20120157420 - Treatment and prevention of secondary injury after trauma or damage to the central nervous system: A method of administering one or multiple medications to human patients with CNS injury through oral or parenteral (including transdermal, intravenous, subcutaneous, intramuscular) routes. Inflammatory and immunological processes have been shown to cause secondary damage to CNS tissues in individuals with acute CNS injury. The present invention administers one or... Agent:

20120157421 - 17beta-alkyl-17alpha-oxy-estratrienes: The invention relates to 17β-alkyl-17α-oxy-oestratrienes of the formula (I), to processes for their preparation, to the use of the 17β-alkyl-17α-oxy-oestratrienes for preparing pharmaceuticals and to pharmaceutical preparations comprising these compounds.... Agent: Bayer Pharma Aktiengesellschaft

20120157422 - Marker: The invention provides a method for identifying whether a pregnant subject has an increased risk of preterm labour comprising measuring the progesterone concentration in a sample obtained from the subject, wherein a reduced progesterone concentration is indicative of an increased risk of preterm labour and delivery.... Agent: King's College London

20120157423 - Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof: e

20120157424 - Treatment of menopause-associated symptoms: Described are estradiol-containing pharmaceutical compositions and, and methods using the same to alleviate menopause-related symptoms, such as hot flushes, by topically administering estradiol at low effective doses.... Agent: Besins Healthcare Sa

20120157428 - Bromodomain inhibitors and uses thereof: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Agent: Constellation Pharmaceuticals, Inc.

20120157429 - Compounds useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent:

20120157433 - Heteroaryl compounds as kinase inhibitors: e

20120157430 - N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.... Agent:

20120157432 - Novel pyrrolidine derived beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent: Merck Sharp & Dohme, Corp.

20120157431 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators: A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.... Agent:

20120157426 - Mutant-selective egfr inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20120157425 - New compounds, pharmaceutical compositions and uses thereof: e

20120157427 - Pyrazole aminopyrimidine derivatives as lrrk2 modulators:

20120157436 - 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as p2x7 modulators: The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain,... Agent:

20120157434 - Antimicrobial heterocyclic compounds for treatment of bacterial infections: e

20120157435 - Antiviral compounds: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and respiratory viruses including the common cold.... Agent: Prosetta Antiviral Inc.

20120157438 - Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators: The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also... Agent: Merck Sharp & Dohme Corp

20120157439 - Raf inhibitor compounds and methods of use thereof: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are... Agent: Array Biopharma Inc.

20120157437 - Vla-4 inhibitory drug: Q represents an optionally-substituted monocyclic or bicyclic nitrogen-containing heterocyclic group having a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents an optionally-substituted bicyclic aromatic hydrocarbon ring group or an optionally-substituted bicyclic aromatic heterocyclic group; A1 represents a nitrogen atom or C—R3d wherein R3d... Agent: Daiichi Sankyo Company, Limited

20120157441 - Inhibitors of the mutant form of kit: The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.... Agent:

20120157440 - Novel fused pyridine compounds as casein kinase inhibitors: e

20120157443 - Bruton's tyrosine kinase inhibitors: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.... Agent: Biogen Idec Ma Inc.

20120157442 - Heteroaryl btk inhibitors: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.... Agent: Biogen Idec Ma Inc.

20120157444 - Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators: The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.... Agent: Allergan, Inc.

20120157445 - Cognitive function: Provided herein are methods, drug formulations, and dosing regimens for improving cognitive function in a normal or cognitively impaired subject. For instance, methods provided herein comprise administering a GABAA receptor antagonist so that peak concentration of the GABAA receptor antagonist occurs when the subject is asleep.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120157446 - Medical use: o

20120157447 - Quinolone carboxylic acids, derivatives thereof, and methods of making and using same: A process of preparing a quinolone carboxylic acid or its derivatives having Formula I, Ia, or IV, as shown herein, comprises using a starting quinolone that already has one or more desired substituents at one or more particular positions on the quinolone ring and preserving the orientation of such substituents... Agent:

20120157448 - Compounds for treating neurodegenerative diseases: The invention provides novel tricyclic compounds of Formula I′ that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.... Agent:

20120157449 - Benzofurane compounds: e

20120157450 - Anhydrate forms of a pyridine derivative:

20120157451 - Raf inhibitor compounds and methods of use thereof: Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Genentech, Inc

20120157452 - 1h-pyrazolo[3,4-b] pyridine compounds for inhibiting raf kinase: Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.... Agent: Array Biopharma Inc.

20120157453 - Raf inhibitor compounds and methods of use thereof: Compounds of Formula II are useful for inhibition of Raf kinases. Methods of using compounds of Formula II and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are... Agent: Array Biopharma Inc.

20120157454 - Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors: There are provided substituted isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The... Agent: Nerviano Medical Sciences S.r.l.

20120157455 - Compounds and compositions for treating cancer: The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also... Agent: Canthera Therapeutics, Inc.

20120157456 - Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase: e

20120157457 - Compositions and methods for inducing neuronal differentiation: The present invention provides compositions and methods for inducing neuronal cell differentiation.... Agent: The Scripps Research Institute

20120157458 - Imidazotriazinone compounds: The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.... Agent:

20120157459 - Novel 3-hydroxy-5-arylisothiazole derivative: e

20120157461 - Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer: There is provided compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of cancer and conditions... Agent:

20120157460 - Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof: e

20120157464 - Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxia: The invention concerns the use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment, prevention or delay of progression of ataxia.... Agent: Novartis Ag

20120157462 - Hydroxamic acid derivatives of aniline useful as therapeutic agents for treating anthrax poisoning: e

20120157465 - Dna methylation inhibitors: A number of DNA methylation inhibitors are described. The DNA methylation inhibitors were identified using a two-component enhanced green fluorescent protein reporter system to screen a compound library containing procainamide derivatives. The DNA methylation inhibitors can be used for cancer therapy and prevention.... Agent: The Ohio State University Research Foundation

20120157467 - Composition and use for phosphodiesterase inhibitors: Compositions and methods for enhancing the aesthetic appearance of the lip or lips of a human achieved by applying to the surface of the lip a composition containing a phosphodiesterase inhibitor, preferably a pyrazolopyrimidinone such as sildenafil or its citrate salt.... Agent:

20120157466 - Heterocyclic compounds with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple... Agent:

20120157468 - Plk inhibitor salts: The present invention relates to novel crystalline, water-soluble salts of a plk inhibitor. Such crystal salts are for example L-tartrate, succinate, phosphate, mesylate, maleate, L-malate, hydrochloride, fumarate (half mole of counterion), fumarate, citrate (half mole of counterion), benzenesulfonate and L-aspartate (half mole of counterion). New crystal forms of the base... Agent: Nerviano Medical Sciences S.r.l.

20120157463 - Chromone derivatives, a process for their preparation and their therapeutic applications: The present invention relates to chromone derivatives, their preparation, their pharmaceutical compositions and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system.... Agent: Pierre Fabre Medicament

20120157469 - Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof: e

20120157470 - Salts and crystalline forms of an apoptosis-inducing agent: Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.... Agent: Abbott Laboratories

20120157471 - Benzimidazole derivatives: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1A, R1B, R1C, R2, R3, R4, R5, RA, RB, RC and X are as defined herein. These novel benzimidazole derivatives are useful in therapy, in particular for treating diseases or conditions mediated by... Agent: Pfizer Inc.

20120157472 - Method for treating colorectal cancer: The present invention relates to a method of treating patients suffering from colorectal cancer characterized by coadministration of BIBF 1120 and BIBW 2992, wherein in said method BIBF 1120 is administered according to a continuous daily regimen and BIBW 2992 is administered according to a weekly alternating on-off regimen, pharmaceutical... Agent: Boehringer Ingelheim International Gmbh

20120157473 - Therapeutic methods and compounds: The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis,... Agent: Dmi Acquisition Corp.

20120157475 - Combination preparation against vertigo: The use of cinnarizine and dimenhydrinate or their physiologically compatible salts in combination is described for the treatment of vertigo of any genesis.... Agent: Hennig Arzneimittel Gmbh & Co. Kg

20120157474 - Methods of identifying and using general or alternative splicing inhibitors: The present invention is based on the discovery of a cell-based system to identify novel modulators of splicing or splicing dependent processes. The cell-based system of the present invention utilizes a fast and highly sensitive reporter, that responds to defects in the splicing machinery itself and is sensitive to changes... Agent: The Trustees Of The University Of Pennsylvania

20120157476 - Oxime compounds: wherein A1 to A3 and R1 to R9 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis... Agent:

20120157477 - Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands: The present invention includes methods, uses, and compounds for treating or preventing L-dopa-induced dyskinesias.... Agent: Targacept, Inc.

20120157478 - Hair care compositions and methods to improve hair appearance: Hair care compositions and methods that can increase the appearance of healthier hair by increasing the appearance of thicker and fuller hair, longer hair, and/or delayed emergence of gray hair. Such compositions can be applied to any areas where healthier hair appearance is desired, such as the scalp or face.... Agent:

20120157479 - 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase: The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase... Agent: Albert Einstein College Of Yeshiva University

20120157480 - Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors: The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. Methods are provided for predicting the sensitivity of tumor cell growth to inhibition by an EGFR kinase inhibitor, comprising assessing whether the tumor cell has undergone an... Agent:

20120157481 - Tricyclic pyrimidine derivatives as wnt antagonists: The present invention relates to compounds having the general formula (I) with the definitions of X1-X3, Y1, Y2, L1, R1 and R2 given below and/or solvates, hydrates, esters and pharmaceutically acceptable salts thereof. Furthermore, the invention relates to the use of said compounds for modulating of the Wnt signalling pathway... Agent: Deutsches Krebsforschungszentrum

20120157482 - Compounds and methods: e

20120157483 - Method for treating liver diseases of various origins: The method provides reduction of the manifestations of cytolysis under the influence of damaging agents and a statistically significant reduction of dysproteinemia, it accelerates restoration of detoxifying processes of the liver, increases induction of endogenic interferon alfa and, consequently, makes the protection of liver cells during hepatitides of various origins... Agent:

20120157484 - Tryptophan hydroxylase inhibitors: Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders:... Agent:

20120157487 - Sulfur derivatives as chemokine receptor modulators: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.... Agent: Allergan, Inc.

20120157485 - Synergistic fungicidal interactions of 5-fluorocytosine and other fungicides: A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula I and (b) at least one fungicide selected from the group consisting of myclobutanil, fenbuconazole, difenoconazole, trifloxystrobin, pentiopyrad, fluopyram, boscalid, mancozeb, and pyrimethanil provides synergistic control of selected fungi.... Agent: Dow Agrosciences LLC

20120157486 - Synergistic fungicidal interactions of aminopyrimidines and other fungicides: A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula I and (b) at least one fungicide selected from the group consisting of myclobutanil, fenbuconazole, difenoconazole, trifloxystrobin, penthiopyrad, fluopyram, boscalid, mancozeb, pyrimethanil, and bixafen provides synergistic control of selected fungi.... Agent: Dow Agrosciences LLC

20120157488 - Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline: wherein the variables R1, R2, R3, R4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as... Agent: Boehringer-ingelheim International Gmbh

20120157489 - Treatment of endometriosis: A pharmaceutical composition comprising quinagolide for the treatment and/or prevention of endometriosis.... Agent:

20120157491 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent: Glaxo Group Limited

20120157490 - N-biarylamides: The invention relates to N-biarylamides useful for the prophylaxis and/or treatment of impairments of perception, concentration, learning and/or memory, and to processes for preparing them, and pharmaceutical compositions containing them.... Agent: Bayer Healthcare Ag

20120157492 - Antibiotic drug: This invention relates to a malic acid salt of (3S,5R)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid. Also disclosed is a method of treating bacterial infection by an effective amount of this salt.... Agent:

20120157493 - Antifungal and antiparasitic indoloquinoline derivatives: “An indoloquinoline wherein the quarternary N-5 atom is a straight C(1-5) chain, a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or... Agent: Florida A&m University

20120157494 - Isoindolyl compounds: x

20120157495 - Benzimidazole derivatives: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzamidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds... Agent:

20120157496 - Stabilized and preserved ketotifen ophthalmic compositions: Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein.... Agent:

20120157497 - Compounds having analgesic and/or immunostimulant activity: The compounds shown by their structural formulas in the specification have analgesic and or immunostimulant activity in mammals.... Agent: Allergan, Inc.

20120157498 - Substituted enaminocarbonyl compounds: The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Bayer Cropscience Ag

20120157499 - Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug: The present invention relates to method of sustained-delivery of an active drug to a posterior part of an eye of a mammal to treat or prevent a disease or condition affecting said mammal, wherein said disease or condition can be treated or prevented by the action of said active drug... Agent: Allergan, Inc.

20120157500 - Jak inhibition blocks rna interference associated toxicities: The instant invention provides a method for treating patients by administering a JAK inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is a JAK2 inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor... Agent:

20120157501 - Isoketal scavengers and mitigation of disorders involving oxidative injury: A method of treating and/or preventing oxidative damage, comprising administering an effective IsoK/NeuroK adduct formation suppressing amount of a phenolic amine compound and/or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.... Agent: Vanderbilt University

20120157502 - Phenanthrenone compounds, compositions and methods: m

20120157503 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic... Agent:

20120157504 - New process: The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.... Agent:

20120157505 - Oral formulations of bendamustine: The present invention is directed to oral formulations of bendamustine, and its pharmaceutically acceptable salts, methods of use thereof, and methods of treatment comprising them.... Agent: Cephalon, Inc.

20120157506 - Novel imidazole-2-benzamide compounds useful for the treatment of osteoarthritis: e

20120157515 - Methods and compositions for the treatment of \"burning feet syndrome\": Disclosed herein Methods and composition for the treatment of an individual with “Burning Feet Syndrome”. Included are the manner and process of making the composition, administration, uses, and effective therapeutic amounts of Pantothenic acid and Alpha-lipoic acid with no adverse side effects. The composition can be used to prophylax (prevent),... Agent:

20120157516 - Novel thiophene compounds for use in therapy: The present invention relates to novel substituted thiophene derivatives useful in therapy of diseases related to misfolded and aggregated proteins.... Agent: Biochromix Pharma Ab

20120157517 - Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof: A pharmaceutical solution of taxanes, its preparation method, a composition comprising said solution and its pharmaceutical combination package are disclosed. Said pharmaceutical solution comprises taxanes, a pH regulator and a solvent, wherein the pH regulator is a water-soluble acid.... Agent: Tianjin Tasly Group Co., Ltd.

20120157518 - Sublingual spray formulation comprising dihydroartemesinin: The invention provides pharmaceutical compositions for the treatment of neoplastic diseases, fluke infestations and Lyme disease, comprising compounds capable of providing dihydroartemesinin and a medium chain triglyceride formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. Also provided are delivery devices containing the compositions.... Agent: Londonpharma Ltd.

20120157519 - Tellerium-containing compounds for treating viral infections: Tellurium-containing compounds identified for use in a method of treating, or prophylaxis against, a viral infection caused by an influenza virus, uses thereof and pharmaceutical kits and pharmaceutical corn positions comprising the same, are disclosed. The tellurium-containing compounds disclosed herein are suitable for co-administration with an antiviral agent.... Agent: Biomas Ltd.

20120157520 - Dioxanes derived from regrouping carbohydrates and c-glycosides, process for obtaining same and uses thereof: The present invention relates to compounds with a dioxane nucleus derived from carbohydrates and C-glucosides, process for obtaining same, to the use of such compounds as cytotoxic and antiproliferative agents and to the use thereof for producing a cancer treatment drug.... Agent: Consejo Superior De Investigaciones Cientificas (csic)

20120157521 - Treatment of macular degeneration: The present invention relates generally to methods for treating macular degeneration, and in particular age-related macular degeneration, involving the use of specific benzofuran based compounds.... Agent: Bonomics Limited

20120157522 - B. anthracis prevention and treatment: mutant b. anthracis lacking luxs activity and furanone inhibition of growth, ai-2 quorum sensing, and toxin production: The present invention pertains to the discovery that B. anthracis possesses a luxS gene that encodes a functional LuxS polypeptide, and that B. anthracis synthesizes a functional AI-2 quorum-sensing molecule. The invention provides mutant B. anthracis bacteria lacking the function of the luxS gene, which do not produce a functional... Agent: New York University

20120157523 - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.... Agent: Xenoport, Inc.

20120157524 - 3-methanesulfonylpropionitrile for treating inflammation and pain: The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention... Agent:

20120157525 - Treating eczema and/or psoriasis: The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.... Agent: Lypanosys Pte Limited

20120157526 - Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate: Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate.... Agent: Ucl Business PLC

20120157527 - Cosmetic use of a jasmonic acid derivative for treating the hair and the scalp: R2 represents a linear saturated or unsaturated hydrocarbon-based radical containing from 1 to 18 carbon atoms, or a branched or cyclic saturated or unsaturated hydrocarbon-based radical containing from 3 to 18 carbon atoms; and also an optical isomer thereof and/or a corresponding salt thereof, in a composition for caring for... Agent: L'oreal

20120157528 - Leave-on nonsolid skin conditioning compositions containing 12-hydroxystearic acid and ethoxylated hydrogenated castor oil: Leave-on non-solid skin conditioning compositions comprising 12-hydroxy stearic acid. Compositions contain 12HSA, yet have a relatively low viscosity, so are suitable for spreading on the skin, and are stable on storage and structurally reversible through temperature cycling.... Agent: Conopco Inc., D/b/a Unilever

20120157529 - Composition and method for prevention, mitigation or treatment of an enteropathogenic bacterial infection: The present invention embraces the use of palmitoleic acid, or a derivative, mimetic, or extract containing the same, to decrease the expression of bacterial virulence factors thereby preventing, mitigating, or treating bacterial infection.... Agent: Trustees Of Dartmouth College

20120157531 - Compositions and methods for lowering triglycerides: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.... Agent: Amarin Pharma, Inc.

20120157530 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharma, Inc.

20120157533 - Magnesium compositions and uses thereof for metabolic disorders: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as... Agent: Magceutics, Inc.

20120157532 - Method of treating or preventing a convulsive disorder in a patient in need thereof: The present invention relates to a method of treating or preventing a convulsive disorder in a patient in need thereof comprising administering said patient with a therapeutically effective amount of an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation once per day in... Agent:

20120157534 - Compositions and methods of treatment for inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or... Agent: The Board Of Regents Of The University Of Oklahoma

20120157535 - Prophylactic and/or therapeutic agent for dysmenorrhea: Disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof. Specifically disclosed is a prophylactic and/or therapeutic agent for dysmenorrhea and/or associated symptoms thereof, which comprises tranilast as an active ingredient thereof.... Agent: Keio University

20120157536 - Composition for transdermal administration of non-steroidal anti-flammatory drug: This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive... Agent: Polytherapeutics, Inc.

20120157537 - Nmda receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau: Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.... Agent:

20120157538 - Compounds for the inhibition of herpes viruses: 3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus... Agent:

20120157539 - Nuclear receptor binding agents: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes... Agent:

20120157540 - Disinfectant and sanitizer formulations: The present invention relates to disinfectant formulations containing: (i) an antimicrobial active agent selected from the group consisting of biguanides, monoguanides, and combinations thereof; (ii) a compound selected from the group consisting of a dialkyldimethyl ammonium salt, an alkyldimethylbenzyl ammonium salt, an alkyldimethyl(ethylbenzyl) ammonium salt, and combinations thereof wherein the... Agent:

20120157541 - Soluble pharmaceutical formulations of n,n-diaminodiphenyl sulfone for optimal use in the treatment of various diseases: The present invention aims to demonstrate that a soluble pharmaceutical formulation can be prepared of N,N′-Diamino-diphenyl sulfone which is useful in the development of an ideal drug for use against cerebral infarction, epilepsy, traumatic spinal cord injury, cranio-encephalic trauma, leprosy, Pneumocystis carinii infections and any condition which requires rapid and... Agent: Universidad Aut&#xd3 Noma Metropolitana

20120157542 - Method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels: The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one... Agent:

20120157543 - Preparation of (r,r)-fenoterol and (r,r)-or (r,s)-fenoterol analogues and their use in treating congestive heart failure: This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of... Agent: The United States Of America As Represented By The Secretary, Department Of Health And Human

20120157544 - Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein: i

20120157545 - Methods for treating skin disorders with topical nitrogen mustard compositions: Provided are methods for treating skin disorders comprising topically applying to the affected skin a composition comprising a nitrogen mustard or a pharmaceutically acceptable salt thereof.... Agent:

20120157546 - Compositions containing aromatic aldehydes and their use in treatments: Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. Some of the compositions are useful in transdermal and other systemic dose forms for treating other inflammatory conditions in mammals.... Agent: Merz Aesthetics, Inc.

20120157547 - Compositions and applications of carotenoids of improved absorption and bioavailability: Micro micellar form of carotenoids or xanthophylls, which show improved absorption and biovailability by living organisms, providing higher levels of carotenoids in the blood stream, and consequently are deposited at the target tissues at a faster rate, and more efficiently than crystalline carotenoids, which does not contain any crystal forms... Agent:

20120157549 - Methods of preventing, treating and diagnosing disorders of protein aggregation: Disclosed are methods of preventing, treating, or diagnosing in a subject a disorder in protein folding or aggregation, or amyloid formation, deposition, accumulation, or persistence consisting of administering to said subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof.... Agent:

20120157548 - Use of cycloaliphatic diols as biocides: Use of diols with a cycloaliphatic group as biocide.... Agent: Basf Se

20120157550 - Drug carriers comprising amphilphilic block copolymers: An aqueous composition comprises an amphiphilic block copolymer, having a hydrophilic block comprising pendant zwitterionic groups and a hydrophobic block, and a biologically active compound associated with the polymer. The polymer is preferably in the form of micelles, and preferably the biological active is a hydrophobic drug. The hydrophilic block... Agent: Biocompatibles Uk Limited

20120157552 - Novel concentrated inverse latex, process for preparing it and industrial use thereof: A composition in the form of a positive latex includes: a) 50-80 wt. % of at least one cross-linked, branched, or linear organic polymer (P), b) 5-10 wt. % of a water-in-oil (W/O) emulsifying system (S1), c) 5-45 wt. % of at least one oil, and d) 0-5 wt. %... Agent: Soci&#xe9 T&#xe9 D'exploitation De Produits Pour Les Industries Chimiques Seppic

20120157551 - Use of polymers: The present invention relates to the use of branched addition copolymers possessing melt or solution viscosities lower than the linear polymer analogues of equivalent or greater weight average molecular weight, compositions comprising said copolymers, methods for their preparation, and he use of novel polymers per se in for example but... Agent: Unilever PLC

20120157553 - Methods for using rebaudioside c as a flavor enhancer: The present invention is directed to the use of one or more rebaudioside C polymorphs, or stereoisomers thereof, to enhance the sweet taste of a flavoring, such as glucosylated steviol glycoside, rebaudioside A, ammoniated glycyrrhizin, neohespherdin dihydrochalcone or thaumatin.... Agent: International Flavors & Fragrances

  
06/14/2012 > 156 patent applications in 116 patent subcategories. invention type

20120149630 - End-modified poly(beta-amino esters) and uses thereof: Poly(beta-amino esters) are end-modified to form materials useful in the medical as well as non-medical field. An amine-terminated poly(beta-amino ester) is reacted with an electrophile, or an acrylate-terminated poly(beta-amino ester) is reacted with a nucleophile. The inventive end-modified polymers may be used in any field where polymers have been found... Agent: Massachusetts Institute Of Technology

20120149631 - Antimicrobial and antibiofilm activity of cathelicidins: The present disclosure relates to peptides, and fragments thereof, conferring antimicrobial and/or antibiofilm growth, as well as products and methodology for using same.... Agent: George Mason Intellectual Properties, Inc

20120149632 - Glycopeptide and lipoglycopeptide antibiotics with improved solubility: The invention relates to derivatives of glycopeptide and lipoglycopeptide antibiotics possessing an altered ionization state with respect to the parent glycopeptide or lipoglycopeptide antibiotic, and having the ability to be regenerated as the parent glycopeptide or lipoglycopeptide antibiotic under physiological conditions. These compounds are useful as antibiotics for the prevention... Agent: The Medicines Company

20120149633 - Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom: Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus,... Agent: University Of North Carolina At Charlotte

20120149634 - Compounds and methods for treating bone disorders and controlling weight: The present invention provides peptides and methods of their use in treating bone disorders and bone-related conditions and in treating obesity.... Agent:

20120149635 - Treatment for obesity: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.... Agent: Unigene Laboratories Inc.

20120149636 - Modified leptin polypeptides and their uses: Modified human leptin polypeptides and uses thereof are provided.... Agent: Ambrx, Inc.

20120149637 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent:

20120149638 - Methods for preventing or treating insulin resistance: The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship... Agent: Cornell Research Foundation, Inc. East Carolina University

20120149639 - Use of a dpp-iv inhibitor to reduce hypoglycemic events: The invention relates to a method to reduce the hypoglycemic events, especially severe hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.... Agent:

20120149641 - Methods and compositions for regenerating articular cartilage: Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.... Agent: Genera Istrazivanja D.o.o.

20120149640 - Peptides modulating the activity of igf-1 and the applications of said peptides: The invention relates to peptides for modulate IGF-1 activity, a pharmaceutical composition comprising them as well as their applications as medicinal products and cell proliferation modulating agents in vitro.... Agent:

20120149642 - Fibrosis inhibitor for implanted organ: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.... Agent:

20120149643 - Safe desmopressin administration: Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome... Agent: Allergan, Inc.

20120149644 - Compositions and methods for treating growth hormone deficiency: The present invention relates to methods of predicting the level of response to treatment with growth hormone in an individual having Growth Hormone Deficiency (GHD) or Turner Syndrome (TS).... Agent: Merck Serono Sa

20120149645 - Compositions and modulation of myocyte enhancer factor 2 (mef2): The disclosure relates to mitochondrial myocyte enhancer factor 2 (MEF2), Parkinson's disease, and other related diseases. In certain embodiments, the disclosure relates to analyzing the levels of mitochondrial MEF2 isoforms and/or its mitochondrial target gene ND6 in peripheral blood cells such as white blood cells as an indicator for neuronal... Agent: Emory University

20120149646 - Long term potentiation with cyclic-glur6 analogs: This invention discloses CN2097-like compositions that facilitate the induction of long-term potentiation (LTP). In one embodiment the method comprises inducing long-term potentiation in a subject by the method of administering a therapeutically effective dose of a CN2907-like compound.... Agent:

20120149647 - Methods for assessing the efficacy of gemcitabine or ara-c treatment of cancer using human antigen r levels: Disclosed are compositions and methods relating to the treatment of a disease with a nucleoside analog, such as gemcitabine or Ara-C, and a polynucleotide construct encoding for an mRNA binding protein, such as Human antigen R.... Agent:

20120149648 - Therapeutic peptidomimetic macrocycles: The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.... Agent: Aileron Therapeutics, Inc.

20120149650 - Diphtheria toxin variant: The present invention relates to methods and compositions of modified variants of diphtheria toxin (DT) that reduce binding to vascular endothelium or vascular endothelial cells, and therefore, reduce the incidence of Vascular Leak Syndrome. One aspect of the present invention relates to a polypeptide toxophore from a modified DT, wherein... Agent: Anjin Group, Inc.

20120149649 - Short-chain cationic polyamino acid and use thereof: e

20120149651 - Caveolin peptides and their use as therapeutics: The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates... Agent: Yale University

20120149652 - Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies: Peptides including post-translational-type modifications, such as phosphorylation or acetylation of one or more amino acids, are provided. Processes for obtaining the peptides, pharmaceutical compositions including the peptides and methods for treating autoimmune diseases using the peptides are also provided.... Agent: Centre National De La Recherche Scientifique

20120149653 - Multifunctional linkers and methods for the use thereof: In accordance with the present invention, novel multifunctional compounds have been developed which have orthogonal reactive groups thereon, thereby facilitating preparation of compounds having multiple functional properties (e.g., a targeting moiety and a biologically active moiety). Such constructs are useful for a variety of applications, e.g., for the delivery of... Agent: Rgo Bioscience LLC

20120149654 - Humic substances and uses thereof in agro-environment: The present invention relates to the two main categories of humic substances, humic acids and fulvic acids and their use for hindering the propagation and/or contamination with prion infectivity both in agricultural and environmental systems.... Agent: Scuola Internazionale Superiore Di Studi Avanzati

20120149655 - Use of jasmonate to treat bladder dysfunction: A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.... Agent: Broady Health Sciences, LLC

20120149656 - Water solution of 20(r) - ginsenoside rg3 pharmaceutical composition and process thereof: A preparation of a kind of 20(R)-ginsenoside Rg3 medicinal composition aqueous solution containing ginsenoside Rg3 0.5˜10 mg/ml: add 0.1-5% of ginsenoside solution to 0.1˜30% of adjuvant A, B{circle around (1)}{circle around (2)}{circle around (5)} at the temperature of 40˜100° C., the ratio of these two is 1:1˜300, add water after... Agent:

20120149755 - Antisense oligonucleotide modulation of raf gene expression: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided.... Agent: Isis Pharmaceuticals, Inc.

20120149757 - Compositions and methods for modulation of smn2 splicing: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.... Agent:

20120149760 - Disabling autophagy as a treatment for lysosomal storage diseases: Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).... Agent:

20120149762 - Gene and protein relating to hepatocellular carcinoma and methods of use thereof: The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory... Agent: Oncotherapy Science, Inc.

20120149754 - Methods for modulating the expression and aggregation of cag-expanded gene product in cells and methods for identifying agents useful for doing the same: This invention provides a method for modulating the expression of a first gene in a cell wherein the first gene is one containing more than 36 CAG trinucleotide repeats and encoding a protein that form polyglutamine-mediated protein aggregation. Suppression of the first gene is achieved by reducing the expression of... Agent: National Yang Ming University

20120149761 - Nucleic acid molecules and uses thereof: Provided in this application are formulations of double stranded RNA molecules and Krebs Cycle analogs that improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA. Also disclosed are methods of treating a primary... Agent: Atossa Genetics, Inc.

20120149758 - Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization: A pharmaceutical composition including as active agent, an antisens oligonucleotide having the sequence SEQ ID NO: 1, wherein the antisens oligonucleotide is in a concentration from about 0.40 mg/ml to about 2 mg/ml and the use thereof for preventing, stabilizing and/or inhibiting blood and lymph vascularization.... Agent: Gene Signal International

20120149759 - Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins): The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Insulin gene (INS), in particular, by targeting natural antisense polynucleotides of an Insulin gene (INS). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders... Agent: Opko Curna, LLC

20120149756 - Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease: Provided are tricyclo-DNA (tc-DNA) AON and methods employing tc-DNA AON for modifying splicing events that occur during pre-mRNA processing. Tricyclo-DNA (tc-DNA) AON are described that may be used to facilitate exon skipping or to mask intronic silencer sequences and/or terminal stem-loop sequences during pre-mRNA processing and to target RNase-mediated destruction... Agent: Universite Pierre Et Marie Curie

20120149764 - Aptamers that bind thrombin with high affinity: The invention provides aptamers capable of binding to thrombin useful as therapeutics for and diagnostics of coagulation related disorders and/or other diseases or disorders in which thrombin has been implicated. The invention further provides materials and methods for the administration of aptamers capable of binding to thrombin.... Agent:

20120149763 - Pharmaceutical composition for treating adverse reactions due to administration of spiegelmers: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for treating undesired physiological adverse reactions due to the administration of a therapeutic molecule containing the L-RNA.... Agent: Freie Universitaet Berlin

20120149765 - Sgk1 as diagnostic and therapeutic target: The invention relates to the utilization of a substance for diagnostic determination of sgk1 (serum and glucocorticoid dependent kinase 1) and to the utilization of an active agent in order to influence sgk1 for therapeutic treatment of diseases associated with disordered activity of the tissue factor and to a diagnostic... Agent:

20120149657 - 2'-fluoro arabino nucleosides and use thereof: A method of treating cancer using certain 2′-fluoro arabino nucleosides is provided. Also provided are compounds represented by the formula: (I & A) wherein R is alkyl; and pharmaceutically acceptable salts thereof; and pharmaceutical compositions containing these compounds.... Agent: Southern Research Institute

20120149658 - Modified pectins, compositions and methods related thereto: The present invention provides compositions of modified pectin and methods for preparing and using them.... Agent: La Jolla Pharmaceuticals Company

20120149659 - Compositions and methods for delivering an agent to a wound: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular... Agent: University Of Memphis Research Foundation

20120149662 - Heterocyclic compounds as janus kinase inhibitors: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I) and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using... Agent: Biocryst Pharmaceuticals, Inc.

20120149660 - Novel n-substituted 5-hydroxypyrollindes as inhibitors of mdm2-p53 interactions:

20120149661 - Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators: wherein X1, X3 and X4 are independently C or N, Y is C—H, N—H or N, wherein the total number of nitrogen atoms represented by X1, X3, X4 and Y is 1 or 2; rings A and B are independently selected from phenyl or pyridyl; R1, R4, R′, R″, n... Agent: Novartis Ag

20120149663 - Boronic acid compositions and methods related to cancer: Disclosed are compounds and methods related to boronic acid derivatives of resveratrol. Certain of these derivatives have enhanced efficacy relative to resveratrol, function as irreversible modulators, and act at the GI/S phase of the cell cycle.... Agent: Georgetown University

20120149664 - Transdermal composition of phosphatidylcholine and method for producing same: Disclosed is a transdermal composition, which uses high-purity phosphatidylcholine that is most susceptible to oxidation and the like, and which exhibits high stability and high migration into the skin. Specifically, a transdermal composition having good stability and migration into the skin is able to be obtained by preparing a transdermal... Agent:

20120149665 - Combination therapy for treating proliferative diseases: A pharmaceutical composition of a tubulin polymerisation inhibitor and an mTOR inhibitor and a method of treating proliferative disease with a combination of a tubulin polymerisation inhibitor and an mTOR inhibitor.... Agent: Bionomics Limited

20120149666 - Compositions and methods of treatment for inflammatory diseases: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or... Agent: The Board Of Regents Of The University Of Oklahoma

20120149667 - Pharmaceutical compositions for treating ibd: A stable and/or synergistic pharmaceutical composition including: a) predinisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration.... Agent: Nordic Pharma

20120149668 - Glucocorticoid receptor alleles and uses thereof: Provided here in are, inter alia, methods of determining whether a patient is resistant or sensitive to glucocorticoid therapy.... Agent: Shriners Hospital For Children

20120149669 - 22-haloacetoxy-homopregnacalciferol analogs and their uses: This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation off HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma also, but not in prostate... Agent: Wisconsin Alumni Research Foundation

20120149670 - 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus... Agent: Bayer Pharma Aktiengesellschaft

20120149671 - 17alpha, 21-dihydroxypregnene esters as antiandrogenic agents: 17α,21-Dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3.20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.... Agent: Cosmo Spa,

20120149672 - Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms: Embodiments of the invention relate generally to the use of compositions comprising methylsulfonylmethane (MSM), and one or more therapeutic agents, for the treatment of drug-sensitive and drug resistant microorganisms. In several embodiments, such compositions are effective in treating drug resistant infectious diseases, for example, MRSA.... Agent:

20120149673 - Inhibitors of store operated calcium release: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC... Agent: Calcimedica, Inc.

20120149675 - 1,2,3-triazole-imidazolecompounds: wherein X, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention provides a method for the manufacture of the compounds of formula... Agent:

20120149677 - Ether benzotriazole derivatives: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is... Agent:

20120149676 - Novel compounds: e

20120149678 - Organonitro compounds for use in treating non-hodgkin's lymphoma and leukemia, and methods relating thereto: The invention provides organonitro compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat non-Hodgkin's lymphoma and certain leukemias in a patient. The compounds, compositions, kits, and methods are contemplated to provide a therapeutic benefit in treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia, acute... Agent:

20120149679 - Sulfonamide derivatives: e

20120149674 - Diaryl substituted alkanes:

20120149684 - Akt inhibitors: The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.... Agent: Eli Lilly And Company

20120149681 - Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune... Agent:

20120149682 - Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors: wherein X, Y, Z, L, A, R5, n, m, and r are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders,... Agent:

20120149680 - Kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20120149683 - Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes: The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ÏV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent:

20120149685 - Composition and method for the treatment of tauopathies: The present invention refers to the use of a specific indolocarbazole compound of general formula (1) or a pharmaceutically-acceptable a salt thereof for the preparation of a pharmaceutical composition for the prevention or treatment of a neurode-generative and/or dementing illness driven by the molecular pathology of microtubule-associate tau such as... Agent: Tautatis, Inc.

20120149686 - Kinase inhibitors and method of treating cancer with same: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.... Agent: University Health Networks

20120149687 - Heterocyclic compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20120149688 - Platelet adp receptor inhibitors: Novel compounds of formulae (I) and (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of... Agent: Portola Pharmaceuticals, Inc.

20120149689 - Method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms: The invention provides a method to effectively wean a woman from hormonal therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for... Agent:

20120149690 - Compositions comprising azelastine and methods of use thereof: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize... Agent: Meda Pharmaceuticals Inc.

20120149691 - Pyrrolo [1,2-b] pyridazine derivatives as janus kinase inhibitors: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using... Agent: Biocryst Pharmaceuticals, Inc.

20120149692 - In vivo studies of crystalline forms of meloxicam: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.... Agent: Thar Pharmaceuticals

20120149693 - Therapeutic compounds: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C and/or RSK disorders, including diseases and disorders mediated by GPCRs and/or RSKs.... Agent: University Of Florida Research Foundation, Inc.

20120149695 - Dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof: Disclosed are dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof. Specifically, the compounds described herein in general formula (I), or their isomers, pharmaceutically acceptable salts or hydrates are provided, wherein each variable has the meaning as defined in the description. Also provided are a process for preparing the... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a.

20120149696 - Ethylene diamine modulators of fatty acid hydrolase: Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating... Agent:

20120149694 - Substituted piperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120149697 - Humic substances and therapeutic uses thereof: The present invention relates to the medical field, in particular to the use of natural organic polyanions, i.e. humic substances, HSs, in the treatment of neurodegenerative diseases, such as Prion disease, Alzheimer's and Parkinson's disease.... Agent: Scuola Internazionale Superiore Di Studi Avanzati

20120149698 - Nouvel compounds: wherein R1, R2, R3, R4 and R5 are defined as mentioned below, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical... Agent: Boehringer Ingelheim International Gmbh

20120149699 - Imidazo[1,2-a]pyridine sulfonamides as trpm8 modulators: e

20120149700 - 2-cyanophenyl fused heterocyclic compounds, and compostions and uses thereof:

20120149701 - Certain chemical entities, compositions and methods: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.... Agent:

20120149702 - Inhibitors of cellular necrosis: The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.... Agent: President And Fellows Of Harvard College

20120149703 - Aza-substituted spiro derivatives: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH2)m2-, —O— or the like,... Agent:

20120149704 - Disubstituted benzamide derivatives as glucokinase (gk) activators: The invention relates to disubstituted benzamide derivatives of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers, prodrugs, metabolites and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating... Agent: Cadila Healthcare Limited

20120149705 - N-thio-anthranilamid compounds and their use as pesticides: wherein the variables and the indices are as defined per the description, processes for preparing the compounds I, pesticidal compositions comprising compounds I, use of compounds I for the control of insects, acarids or nematodes, and methods for treating, controlling, preventing or protecting animals against infestation or infection by parasites... Agent: Basf Se

20120149706 - Inhibition of p38 kinase activity using substituted heterocyclic ureas: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.... Agent:

20120149707 - Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same: The present invention relates to an alpha-arylmethoxyacrylate derivative, a preparation method thereof and a pharmaceutical composition comprising the same, and the alpha-arylmethoxyacrylate derivative is inhibitory of HIF, which plays an important role in the regulation of genes associated with energy metabolism, vasomotion, angiogenesis and apoptosis and in the response of... Agent: Oscotec Inc.

20120149708 - Modulators of viral transcription, and methods and compositions therewith: The substituent groups R1, R2, R3, X, Y, Z, A and B are as defined above. Also contemplated is a method for treating or preventing a HIV-1 infection in a subject, by administering a therapeutically effective amount of at least one compound according to Formula I, as well as a... Agent: George Mason University

20120149709 - Pyrazinoisoquinoline compounds: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the... Agent: Concert Pharmaceuticals, Inc.

20120149711 - Piperidine derivatives used as orexin antagonists: This invention relates to heteroarylamine methyl substituted piperidine derivatives (I) and their use as antagonists of human orexin.... Agent: Glaxo Group Limited

20120149710 - Sortase a inhibitors: i

20120149712 - Methods for improving kidney function: The invention relates to methods for improving renal (kidney) function. Methods for decreasing blood urea nitrogen (BUN), for increasing glomerular filtration rate (GFR), and for decreasing serum creatinine are also provided.... Agent: Fibrogen, Inc.

20120149713 - Oral films comprising 7-[4-[4-(2,3-dichlorophenyl) piperazin-1-l]butoxy]-3,4-dihydro-1h-quinolin-2-one base or salts or hydrates thereof: An oral film comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one base or salts or hydrates thereof.... Agent: Hexal Ag

20120149714 - Effects of inhibitors of fgfr3 on gene transcription: Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.... Agent:

20120149715 - Compounds and methods for the treatment of viral infections: High throughput and virtual screening methods are disclosed that can identify potential anti-viral agents. The virtual screening methods identify agents that interact with a viral nucleoprotein binding site. The high throughput methods identify compounds that inhibit viral infection by binding to viral nucleoprotein. Also disclosed are pharmaceutical formulations useful for... Agent:

20120149716 - Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis: Methods of treating, preventing, and managing tuberculosis and other related disorders are disclosed. The methods comprise the administration of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, hydrate, clathrate, stereoisomer, or prodrug thereof, optionally in combination with a second active agent and/or other conventional therapies. Pharmaceutical compositions, single unit... Agent:

20120149717 - Diarylmethyl piperazine derivatives, preparations thereof and uses thereof: t

20120149718 - Amido compounds:

20120149719 - Bitter taste masking dosage form: A powder-particle dosage form obtained by granulating an excipient and/or a disintegrating agent with a liquid in which a bitter taste masking base is dissolved and/or suspended, and a drug having solubility in water (20° C.) of not higher than 1 g/mL is dissolved or suspended, or a tablet obtained... Agent:

20120149720 - Valacyclovir formulations: The present invention relates to taste-masked pharmaceutical formulations of valacyclovir. The present invention also relates to process of preparation of valacyclovir suspensions, solutions and dry powder for reconstitution.... Agent: Ranbaxy Laboratories Limited

20120149721 - Methylpyrrolopyrimidinecarboxamides: e

20120149722 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Avila Therapeutics, Inc.

20120149723 - 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder: This invention relates to heteroaryloxy 5-methyl substituted piperidine derivatives and their use as pharmaceuticals.... Agent:

20120149724 - Modulating endogenous beta-endorphin levels: Systemic beta-endorphin can be elevated in response to cutaneous irradiation, including ultraviolet and ionizing radiation. Increases in systemic beta-endorphin levels associated with cutaneous irradiation can be modulated with opiate receptor antagonists, particularly compounds that antagonize opioid receptor binding by beta endorphin.... Agent: The General Hospital Corporation

20120149725 - Anhydrate ot tiotropium bromide: Novel Anhydrate The present invention relates to a novel form of anhydrous tiotropium bromide, processes for the preparation of anhydrous tiotropium bromide, pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions.... Agent: Generice (uk) Limited

20120149726 - Crystal forms of kinase inhibitors: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.... Agent: Abbott Laboratories

20120149727 - Prasugrel in non-crystalline form and pharmaceutical composition thereof: The present invention relates to prasugrel or a pharmaceutically compatible salt thereof, compositions that contain this active substance and pharmaceutical compositions that contain this active substance or a composition containing this active substance. The present invention further relates to methods for producing the novel compositions.... Agent:

20120149729 - Metalloenzyme inhibitor compounds: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.... Agent: Viamet Pharmaceuticals, Inc.

20120149730 - Methods and compositions using racemic, (r)-, and (s)-fexofenadine in combination with leukotriene inhibitors: Methods and pharmaceutical compositions employing a terfenadine metabolite and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma, or symptoms thereof. Also included are methods and compositions employing a terfenadine metabolite, a leukotriene inhibitor, and a decongestant for the treatment or prevention of... Agent:

20120149728 - Novel fumarate salts of a histamine h3 receptor antagonist: The disclosure relates to fumarate salts of 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, to pharmaceutical compositions thereof, processes for making the same, and methods of use thereof.... Agent: Sanofi

20120149731 - New medical use: e

20120149732 - Multifunctional linkers and methods for the use thereof: In accordance with the present invention, novel multifunctional compounds have been developed which have orthogonal reactive groups thereon, thereby facilitating preparation of compounds having multiple functional properties (e.g., a targeting moiety and a biologically active moiety). Such constructs are useful for a variety of applications, e.g., for the delivery of... Agent:

20120149733 - Piperidinyl compound as a modulator of chemokine receptor activity:

20120149734 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent:

20120149735 - 1,4-dihydropyridine derivatives and their uses: The present invention relates to 1,4-dihydropyridine derivatives of the formula (I) and their uses in the treatment and/or prevention of diseases and disorders directly or indirectly associated with the modification (increase or decrease) of the activity of the cannabinoid receptor 2 (CB2).... Agent: Universite Lille 2 Droit Et Sante

20120149736 - Enzyme inhibitors: Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intra-cellular carboxylesterase enzymes to a carboxylic acid group; R2 and... Agent: Chroma Therapeutics Ltd.

20120149738 - Novel inhibitors of proliferation and activation of signal transducer and activators of transcription (stats): Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.... Agent: Board Of Regents, The University Of Texas System

20120149739 - Pharmaceutical depot for n-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide: A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.... Agent: Astrazeneca Ab

20120149740 - Pharmaceutical depot for n-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide: A pharmaceutical depot comprising (i) N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.... Agent: Astrazeneca Ab

20120149737 - Therapeutic aryl-amido-aryl compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor α (RARα) agonists. The present invention also pertains to pharmaceutical compositions... Agent: King's College London

20120149741 - Treatment of duchenne muscular dystrophy: There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or more halogen, hydroxyl or alkoxy groups; R9 represents... Agent: Summit Corporation PLC

20120149742 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20120149743 - Selenophene and selenazole carboxylic acid derivatives: Derivatives of selenophene and selenazole heterocycles are disclosed. The compounds are useful as inhibitors of D-amino acid oxidase (DAO) and in the treatment of neurodegenerative and psychiatric diseases and disorders.... Agent: Ironwood Pharmaceuticals, Inc

20120149744 - Anti-mitotic anti-proliferative compounds: Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof.... Agent: University Of Medicine And Dentistry Of New Jersey

20120149745 - Antimycotic pharmaceutical composition: A pharmaceutical composition which comprises 1) a compound represented by the following general formula (1) and/or a salt thereof; and 2) a ketone such as methyl ethyl ketone. Preferably, the compound represented by the following general formula (1) is luliconazole, where R1═R2=a chlorine atom: where R1 and R2 each independently... Agent: Pola Pharma Inc.

20120149746 - Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases: The present invention relates to method of treating retinal diseases in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Allergan, Inc.

20120149747 - Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Allergan, Inc.

20120149748 - Pharmaceutical cream compositions and methods of use: The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions.... Agent: Allergan, Inc.

20120149749 - Method of treating thrombocytopenia: Invented is a method of treating thrombocytopenia in a human in need thereof which comprises the administration of a therapeutically effective amount of a 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid to such human.... Agent:

20120149750 - Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof: v

20120149751 - Antiviral drugs for treatment of arenavirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused... Agent: Siga Technologies, Inc.

20120149752 - Kit for balancing neurotransmitter levels: The teachings provided herein generally relate to formulations, systems, and methods that have the ability to remit deficiencies and imbalances in a subject's serotonin and dopamine levels. The teachings relate to the preparation and uses of a formulation comprising a serotonergic agent or dopaminergic agent in a form capable of... Agent:

20120149753 - Use of novel compounds from fruiting body of antrodia camphorata for treating an inflammatory disorder: Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions... Agent: Well Shine Biotechnology Development Co,, Ltd.

20120149767 - Connection device for a submersible connector: The invention relates to a device (1) for connecting/disconnecting a submersible connector (100) provided with a male portion (101) and a female portion (102), to a related connection/disconnection method, as well as to the various potential uses of said device. The device includes means (11, 12) for moving at least... Agent: Institut De Recherche Pour Le Developpement

20120149766 - Dietary and pharmaceutical compositions comprising a sage extract containing a mixture of tricyclic diterpenes and their derivatives and their uses: The present invention refers to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to III, preferably to a sage extract containing a mixture of tricyclic diterpene (derivative)s of the formulae I to IV, more preferably to a sage extract containing a mixture of tricyclic... Agent: DsmIPAssets B.v.

20120149768 - Pkc-activating compounds for the treatment of neurodegenerative diseases: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or... Agent: Blanchette Rockefeller Neurosciences Institute.

20120149769 - Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders: The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the... Agent: Genmedica Therapeutics Sl

20120149770 - Antimicrobial preservation of propofol emulsions: The invention provides intravenous formulations of propofol in an oil-in-water emulsion, having a combination of preservatives.... Agent: The Medicines Company

20120149771 - Method for treating airway hyper-responsiveness with lipoxin analogs: The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway... Agent: The Brigham And Women's Hospital

20120149772 - Process for the preparation of fesoterodine or a salt thereof: A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.... Agent: Diphara Francis S.r.l.

20120149773 - Composition for skin improvement comprising hexamidines and retinoids: Disclosed is herein a composition comprising hexamidines, derivatives thereof, or pharmaceutically acceptable salts thereof; and retinoids, derivatives thereof, or pharmaceutically acceptable salts thereof, as an active ingredient. The composition of the present invention has effects for preventing, improving or treating acne; controlling sebum; pore-controlling; and preventing, improving or treating skin... Agent: Amorepacific Corporation

20120149777 - Compositions and methods for improving cellular survival and reducing apoptosis after ischemic episode in the brain: Compositions and methods for enhancing vascular integrity in animals are disclosed. The compositions and methods, which utilize long chain polyunsaturated fatty acids and nitric oxide releasing compounds are also effective for reducing ischemia-induced brain injury in an animal.... Agent:

20120149774 - Compositions and methods for nutrient delivery: The present disclosure provides compositions and methods for delivering nutrients to subjects requiring small-volume nutritional support, such as preterm infants. The compositions may comprise an emulsion of docosahexaenoic acid (DHA) and arachidonic acid (ARA). The nutritional compositions are useful, for example, in correcting nutritional deficiencies by increasing a subject's intake... Agent:

20120149775 - Methods for preventing and improving skin elastic property loss: The present invention is directed to method for preventing and improving an aggravation of a skin condition accompanied with a skin elastic property loss by suppressing an increase in, or inhibiting the physiological activity of, palmitic acid. The present invention provides a cosmetic method for preventing and improving wrinkling and... Agent: Shiseido Company, Ltd.

20120149776 - Preparation for sun protection: The invention relates to the use of norbixin and an urucum extract enriched in bixin and/or norbixin as a food. The invention also provides a food preparation comprising norbixin, bixin or an extract comprising at least bixin or norbixin, the preparation being intended to be administered orally, for the protection... Agent:

20120149778 - Compounds: The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar′ are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis... Agent: University Court Of The University Of St. Andrews

20120149779 - High concentration local anesthetic formulations: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful... Agent: Arcion Therapeutics, Inc.

20120149780 - Method of use of vitamin k as energy enhancer in diverse disease states: The invention relates to Vitamin K, its derivatives and combinations to increase the energy levels in diverse disease states and life style disorders, which are characterized by low energy level due to inadequate VO2max, and pO2 and low availability of ATP molecules. VO2max, peak oxygen uptake, is intimately connected to... Agent:

20120149782 - Carotenoid compositions containing modified gum acacia: Compositions containing modified gum acacia, less than 40% oil and carotenoids, where the gum acacia has been subjected to a heat-treatment at a temperature between 100° C. and 115° C. for 1 to 38 hours. These compositions allow preparation of emulsions having a very high color intensity and color stability... Agent: Dsm Assets B.v

20120149781 - Stem cell differentiation using novel light-responsive hydrogels: This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases... Agent: Rutgers, The State University Of New Jersey

20120149784 - Tabletting of erythritol and isomalt: Erythritol is granulated together with from 10% w/w to 50% w/w isomalt. Chewable tablets are prepared and the corresponding process is described.... Agent: Cargill ,incorporated

20120149783 - Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa: The present invention is directed to water-in-oil (W/O) emulsion compositions containing gellan gum which provide an enhanced rate of release of active ingredients for delivery to the skin or mucosa.... Agent: Dpt Laboratories, Ltd.

20120149785 - Method of estimating sepsis risk in an individual with infection: A method of estimating sepsis risk in an individual with infection comprises a step of assaying a biological sample from the individual for an IL-2 or IL-7 mRNA value, and correlating the mRNA value with sepsis risk. The IL-2 and IL-7 mRNA values are quantified by absolute quantification of mRNA... Agent: The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe

  
06/07/2012 > 209 patent applications in 148 patent subcategories. invention type

20120142580 - Opioid receptors stimulating compounds (thymoquinone, nigella sativa) and food allergy: The present invention relates generally to the fields of food allergy and nutrition. It was found that the stimulation of opioid receptors could be used to treat or prevent food allergy. One embodiment of the present invention concerns hence the use of an opioid receptor stimulating compound like thymoquinone or... Agent: Nestec S.a.

20120142581 - Polymer formulations for delivery of bioactive materials: PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery.... Agent: Landec Corporation

20120142582 - Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.... Agent:

20120142583 - Methods of inhibiting and treating bacterial biofilms by metal chelators: The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm.... Agent: University Of Iowa Research Foundation

20120142584 - Novel transporter constructs and transporter cargo conjugate molecules: The present invention relates to novel transporter constructs of the generic formula (I) DlLLLxDm(LLLyDn)a and variants thereof. The present invention also refers to transporter cargo conjugate molecules, particularly of conjugates of the novel transporter constructs with a cargo moiety, e.g. proteins or peptides, nucleic acids, cytotoxic agents, organic molecules, etc.... Agent: Xigen, S.a.

20120142585 - Leptin antagonist and methods of use: This invention provides compounds that are true antagonists of the leptin receptor, in the presence and the absence of native leptin or another leptin receptor binder. These compounds may be used to inhibit leptin receptor activity, promote growth arrest or death of leptin receptor-positive cancer cells, or monitor or detect... Agent: Temple University-of The C0mmonwealth System Of Higher Education

20120142586 - Treatment for obesity: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.... Agent: Unigene Laboratories Inc.

20120142588 - Hsp therapy in conjunction with a low antigenicity diet: The present invention relates to a method for suppression, prevention, delaying the onset or treatment of diabetes, by administering to an individual in need thereof a fragment of Hsp60 or analog thereof in conjunction with a low antigenicity diet. The invention is exemplified using DiaPep277™, an analog of residues 437-460... Agent: Andromeda Biotech Ltd.

20120142587 - Liquid enteral nutritional composition with a low monovalent metal ion content: Heat-treated liquid enteral nutritional composition with a low monovalent metal ion content are provided that contain micellar casein and optionally caseinate, and in which the total amount of monovalent metal ions is less than 25 mg/g of protein. Also, heat-treated liquid enteral nutritional compositions are disclosed comprising 10 to 20... Agent: N.v. Nutricia

20120142590 - Methods and compounds regulating the erythroid response to iron deficiency: The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment... Agent: University Of Virginia Patent Foundation

20120142589 - Tissue-protective cytokines for the protection, restoration and enhancement of responsive cells, tissues and organs: Methods and compositions are provided for protecting or enhancing a responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of a tissue protective cytokine.... Agent: The Kenneth S. Warren Institute, Inc.

20120142591 - Method of treating intraoccular tissue pathologies with nerve growth factor: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the... Agent:

20120142592 - Nasal calcitonin formulations containing chlorobutanol: An aqueous solution of calcitonin suitable for intranasal administration comprised of calcitonin, chlorobutanol at a concentration of less than 0.4% weight/weight, and water and having a pH of less than 4 with the proviso that benzalkonium chloride is not present in the solution. The aqueous solution of calcitonin can be... Agent: Par Pharmaceutical, Inc.

20120142593 - Factor viii variants and methods of use: A Factor VIII fusion protein or a Factor VIII fusion heterodimer comprising Factor VIII in which an amino acid sequence of a modulator is present in the B-domain, or an amino acid sequence of a modulator replaces some or all of the amino acid sequence of the B-domain is disclosed.... Agent: Bayer Healthcare LLC

20120142594 - Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.... Agent: Nektar Therapeutics

20120142595 - Tissue protective peptides and uses thereof: Provided herein are tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are generally located on or within the region of the cytokine receptor ligand that faces away from a receptor complex while the ligand is bound to the receptor.... Agent: Araim Pharmaceuticals, Inc.

20120142596 - Agent for stimulating mobilization of endothelial progenitor cells: The present invention provides a composition for stimulating the mobilization of endothelial precursor cells, which comprises substance-P (SP). Substance-P according to the invention exhibits an activity of stimulating the mobilization of endothelial precursor cells from the bone marrow, thereby stimulating vasculogenesis. Thus, substance-P exhibits excellent effects on the prevention or... Agent:

20120142597 - Biomolecular coating for implants: Methods and compositions are provided for improving tissue growth and device integration in vivo. Substrates and devices coated with an α2β1 or α5β1 integrin-specific ligand are provided. The substrates and devices coated with an α2β1 or α5β1 integrin-specific ligand are shown to have greater tissue formation on the surface relative... Agent: Georgia Tech Research Corporation

20120142598 - Edible compositions for preventing hair loss: The present invention provides compositions comprising hydrolyzed gelatin or a mixture of hydrolyzed gelatin and gelatin, and the same compositions for use in methods comprising administering a low dose of the compositions useful in prophylaxis and treatment of hair loss in humans and shedding in animals. The compositions provide a... Agent:

20120142599 - Extract of r. miehei: Topical compositions comprising extracts of Rhizomucor miehei that are substantially devoid of acid-protease activity and their use in treating dermatologic conditions, including reducing the appearance of signs of skin aging.... Agent: Active Organics, Inc.

20120142600 - Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to... Agent: The Regents Of The University Of California

20120142601 - Modified peptides and uses thereof: The invention includes compounds that are useful in treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain. The invention also includes methods for treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain in a subject in need thereof.... Agent: Musc Foundation For Research Development

20120142603 - Bioadhesive patch for sutureless closure of soft tissue: Provided herein are compositions and methods for treating soft tissue injuries using a patch having a polymer on its surface linked to polypeptides having a disintegrin domain. The polypeptides having a disintegrin domain can include contortrostatin, vicrostatin, and ADAM derived polypeptides. Compositions of the invention can be used for the... Agent: University Of Southern California

20120142602 - Composition and method for preventing or treating a tauopathy: The present invention is a composition and method for the prevention and treatment of a tauopathy. The composition of the invention includes N-terminal amino acid residues of the tau protein, which have been identified as being involved in toxic activation of a PP1/GSK3 signaling cascade and inhibition of fast axonal... Agent: The Board Of Trustees Of The University Of Illinois

20120142604 - Novel applications of hip/pap or derivatives thereof: e

20120142605 - Methods of treating psoriasis: The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid.... Agent: Amgen Inc.

20120142606 - Tumor targeting peptides, therapeutic and diagnostic compositions compressing the peptides: The present invention is directed to peptides having affinity for tumor cells. The peptides are useful in pharmaceutical compositions in particular for the treatment of cancer. Further, the peptides are useful in diagnostic compositions, in particular for the diagnosis and imaging of cancer. The peptides according to the present invention... Agent:

20120142607 - Antibodies and molecules derived therefrom that bind to steap-1 proteins: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent:

20120142609 - Non human animal models for increased retinal vascular permeability: The present invention relates to a non human animal model for increased retinal vascular permeability wherein said increased retinal vascular permeability is induced by inhibiting in Müller cells of said animal the expression of a gene encoding for Dp71 or a dystrophin associated protein (DAP). Furthermore, the present invention relates... Agent:

20120142608 - Rca locus analysis to assess susceptibility to amd and mpgnii: The invention relates to gene polymorphisms and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD and/or MPGNII. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention... Agent: University Of Iowa Research Foundation Corporation

20120142610 - Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of ‘IQ motif containing GTPase activating protein’ (IQGAP), in particular, by targeting natural antisense polynucleotides of ‘IQ motif containing GTPase activating protein’ (IQGAP). The invention also relates to the identification of these antisense oligonucleotides and their... Agent: Opko Curna, LLC

20120142612 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc.

20120142611 - Repeat protein from collection of repeat proteins comprising repeat modules: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein... Agent: Universitat Zurich

20120142613 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway: The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressed cells.... Agent:

20120142614 - Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis: A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one... Agent:

20120142615 - Methods related to the treatment of neurodegenerative and inflammatory conditions: The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and/or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And

20120142616 - Antineoplastic hydrogels, and enzyme-instructed preparations thereof: Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of... Agent:

20120142617 - Antiviral therapeutic agents: s

20120142618 - Ketogenic saccharides: A novel ketogenic compound is provided having general formula (R(OCH(CH3)CH2C(O))nO)m-A wherein n is a integer between I and 10, m is an integer of 1 to 200,000, A is a monosaccharide, polysaccharide or oligosaccharide residue and R is selected from the group consisting of H, C1-C6 alkyl and acetoacetyl-... Agent: Btg International Limited

20120142619 - Medicinal carbohydrates for treatment of respiratory conditions: The present invention relates to a method and compounds of Formula (1) and/or (2) or their pharmaceutically acceptable inorganic or organic salt thereof, and their compositions for treating respiratory conditions including post viral/bacterial infections, acute/chronic bronchitis, COPD, cystic fibrosis, and inflammatory conditions. It has been found by the applicants that... Agent: Australian Blomedical Company Pty Ltd,

20120142620 - Core 2 glcnac-t inhibitors: e

20120142621 - Purified ethyl ester sophorolipid for the treatment of sepsis: A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola. The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then... Agent: Biomedica Management Corporation

20120142622 - Stambomycin and derivatives, their production and their use as drugs: The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.... Agent: University Of Warwick

20120142624 - Akt phosphorylation at ser473 as an indicator for taxane-based chemotherapy: Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

20120142623 - Compositions and methods for predicting inhibitors of protein targets: Compositions and methods are provided for predicting inhibitors of protein targets related to treatment of infectious disease, for example, bacterial, viral, or parasitic diseases. Methods are provided for predicting inhibitors of protein targets related to treatment infectious disease, for example, microbial disease, utilizing a docking with dynamics protocol to identify... Agent:

20120142755 - Compositions for preventing, reducing or treating keratinocyte-mediated inflammation: m

20120142753 - Diagnosis and treatment of adrenocortical tumors using human microrna-483: Disclosed herein are methods of diagnosing and treating a malignant adrenocortical tumor, including adrenocortical carcinoma. In some examples, methods of diagnosing a malignant adrenocortical tumor include detecting expression of at least one microRNA (miR) gene product, such as miR-100, miR-125b, miR-195, miR-483-3p, miR-483-5p and IGF2 mRNA in a sample obtained... Agent: The United States Of America As Represented By The Secretary, Department Of Health And Human Service

20120142754 - Modulation of timp1 and timp2 expression: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly of tissue inhibitor of metalloproteinase 1 and of tissue inhibitor of metalloproteinase 2 (TIMP1 and TIMP2, respectively). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering... Agent: Nitto Denko Technical Corporation

20120142756 - Mrna for use in treatment of human genetic diseases: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.... Agent:

20120142757 - Rnai modulation of aha and therapeutic uses thereof: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Alnylam Pharmaceuticals, Inc.

20120142758 - Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Down Syndrome Gene, in particular, by targeting natural antisense polynucleotides of a Down Syndrome Gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders... Agent: Opko Curna,, LLC

20120142760 - Compositions and methods for regulated protein expression in gut: The invention provides compositions and methods useful for treating disorders treatable by producing a protein in a regulatable manner in a mucosal cell or tissue of an animal. The treatment methods include in vivo and ex vivo methods, including transplanting in vitro transformed cells that secrete the protein into a... Agent: Engene, Inc.

20120142762 - Method for preventing and treating cardiovascular diseases with brca1: Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention of cardiovascular diseases.... Agent: St. Michael's Hospital And King Saud University

20120142764 - Multi-cistronic shrna expression cassette for suppressing single or multiple target genes: The present invention relates to one multi-cistronic shRNA for suppressing single or multiple target genes, and more particularly, to a multi-cistronic shRNA expression cassette, an expression vector comprising the multi-cistronic shRNA expression cassette, cells transduced with the multi-cistronic shRNA expression vector, a composite of the expression vector and a carrier,... Agent:

20120142763 - Nucleic acid delivery compositions and methods of use thereof: This disclosure relates to nucleic acid constructs modified to have a reduced net anionic charge. The constructs comprise phosphotriester and/or phosphothioate protecting groups. The disclosure also provides methods of making and using such constructs.... Agent: The Regents Of The University Of California

20120142761 - Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm: The invention provides nine oligonuleotides with sequences of SEQ ID NO:1-9 or their functional homologues or a composition comprising the same and a method for treating B cell neoplasm by using the oligonuleotides or their functional homologues or the composition comprising the oligonuleotides. The oligonuleotides induce the apoptosis of B... Agent: Changchun Huapu Biotechnology Co., Ltd.

20120142759 - Soluble thf receptors and their use in treatment of disease: The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully.... Agent:

20120142765 - Sphingosine-bound sirna: The invention relates to novel oligomer analogues and their use in oligonucleotide-based therapies. More specifically, the invention concerns oligonucleotides carrying lipid molecules and their use as potential inhibitors of gene expression.... Agent: Sylentis S.a.u.

20120142625 - Substituted purine and 7-deazapurine compounds: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in... Agent: Epizyme, Inc.

20120142626 - Compounds: Disclosed herein are 2′-spiro-nucleosides and derivatives thereof useful for treating a subject infected by hepatitis C virus or dengue virus.... Agent: Pharmasset, Inc.

20120142627 - Monophosphate prodrugs of dapd and analogs thereof: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV and HBV, in human patients or other animal hosts. The compounds are certain 6-substituted-2-amino-purine dioxolane monophosphates or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof.... Agent: Rfs Pharma, LLC

20120142628 - Methods for treating crepitus: Methods for treating and/or preventing crepitus and other joint problems using hyaluronic acid based formulations are provided.... Agent: Allergan, Inc.

20120142629 - Pharmaceutical composition for relieving pain: t

20120142630 - Process for purifying guar: The present invention relates to processes for purifying guar comprising combining borate and guar in an aqueous solution and treating the aqueous solution with an organic solvent to induce precipitation of purified guar. Another embodiment of the present invention is directed to ophthalmic formulations comprising purified guar produced by the... Agent: Alcon Research, Ltd.

20120142631 - Medicinal antidiaper rash cream incorporating a biopolymer and a process to make it: e

20120142632 - Diagnostic and prognostic assay: The present disclosure relates generally to the field of diagnostic and prognostic assays for diseases and conditions of the systemic vasculature. The present disclosure teaches an assay for identifying such a disease or condition of the systemic vasculature as well as classifying and determining the state or stage of the... Agent: St. Vincent's Institute Of Medical Research

20120142633 - Methylpyrrolopyridinecarboxamides: e

20120142634 - Method of treating cancer with a combination of a proteasome inhibitor and salubrinal: The disclosure provides methods for treating or preventing a cancerous condition, such as multiple myeloma, by administering a therapeutically effective combination of a proteasome inhibitor and salubrinal.... Agent: Mount Sinai School Of Medicine Of New York University

20120142635 - Oxazolidinone-quinolone hybrid antibiotics: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:... Agent: Morphochem Aktiengesellschaft Fur Kombinatorische Chemie

20120142636 - Novel glucokinase activators and methods of using same: e

20120142637 - Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-(1h)- one and derivatives thereof: A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton... Agent: The University Of Kansas

20120142638 - Combination of organic compounds: p

20120142639 - Oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142640 - Alkyne and alkene derivatives as sphingosine 1-phosphate-1 receptor modulators: The present invention relates to novel alkyne and alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142641 - Targetted drug delivery to the bone: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.... Agent: Nanyang Technological University

20120142643 - Clonidine and gaba compounds in a biodegradable polymer carrier: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis,... Agent: Warsaw Orthopedic, Inc.

20120142642 - Novel oxime derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142644 - Method for producing phytosterol/phytostanol phospholipid esters: The present invention relates to a method of producing a phytosterol ester and/or a phytostanol ester comprising: a) admixing a phospholipid composition comprising at least between about 10% to about 70% plant phospholipid and at least about 5% water; a lipid acyltransferase; and a phytosterol and/or a phytostanol; and b)... Agent:

20120142645 - Neuroactive steroid compositions and methods of use for lowering cholesterol: Methods for ameliorating a symptom associated with hypercholesterolemia, hyperlipidemia, or both in a subject. In some embodiments, the methods include administering to a subject in need thereof an effective amount of a composition comprising pregnenolone (PG), allopregnanolone (ALLO), dehydroepiandrosterone (DHEA), progesterone (PROG), precursors thereof, metabolites thereof, pharmaceutically acceptable salts thereof,... Agent:

20120142649 - Compositions and methods for delivering clonidine and bupivacaine to a target tissue site: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release bupivacaine or lidocaine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc... Agent: Warsaw Orthopedic, Inc.

20120142650 - Method for treating lung disease: Methods of treating lung diseases comprising administering inducers of NAD(P)H:quinone oxidoreductase 1 (NQO1) are disclosed. Inducers of NQO1 include naphthoquinones such as β-lapachone. Methods of predicting whether a subject with a lung disease will respond to treatment with a naphthoquinone are also described herein.... Agent:

20120142648 - Methods for delivering clonidine compositions in biodegradable polymer carrier and local steriods to a target tissue site: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a steroid at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic... Agent: Warsaw Orthopedic, Inc.

20120142646 - Novel compounds 621: f

20120142647 - Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases: The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically... Agent: Galleon Pharmaceuticals, Inc.

20120142651 - Method of treatment of allergic rhinitis: e

20120142652 - Compositions and methods for localized therapy of the eye: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye.... Agent: Allergan, Inc.

20120142653 - C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.... Agent: Bristol-myers Squibb Company

20120142654 - Prognostic marker for mamma carcinoma: The invention provides an analytical method for the determination of the susceptibility of a human patient suffering from breast cancer to anti-cancer treatment by providing an analytical method for determining the genetic predisposition of a patient in respect of susceptibility, e.g. responsiveness, to anti-cancer treatment, especially treatment using at least... Agent: Medizinische Hochschule Hannover

20120142655 - Novel crystal form of an organic compound and process for the preparation thereof: The present invention relates to novel crystalline Form II of 17α-acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as CDB-4124), processes for the preparation thereof and pharmaceutical compositions comprising it. Form II can be crystallized from different medium such as esters of C1-C4 alcohols and carboxylic acids, ketones, cyclohexane, acetonitrile, dimethylformamide, dimethyl sulfoxide, water and... Agent:

20120142656 - Buccal application system comprising 17a-estradiol: The invention relates to application systems for buccal application, comprising 17α-estradiol in a dosage of 50 to 400 μg, preferably 200 to 400 μg, particularly preferably 300 μg, together with one or more pharmaceutically acceptable additives or media for implementing the treatment or minimization of hot flashes in women having... Agent: Bayer Pharma Aktiengesellschaft

20120142657 - Gaba-steroid antagonists and their use for the treatment of cns disorders: Compounds exhibiting 3alpha-hydroxy-5alpha/beta-steroid blocking action with no or only low antagonism against the gamma-aminobutyric acid (A) receptor (GABA-A), and compounds exhibiting partial antagonism against said receptor are presented. Methods for the prevention, treatment and/or alleviation of various CNS-disorders are suggested, as well as pharmaceutical compositions for such use.... Agent: Umecrine Ab

20120142658 - Therapeutical use of ternary complexes of valproic acid: A method of treating a human subject having a condition responsive to valproic acid therapy, includes administering to the subject an effective amount of a metal-based ternary complex of valproic acid with nitrogen donor ligands, in particular with diimines or diamines.... Agent: Universite Paris-sud Xi

20120142659 - Compounds and their use as ikach blockers: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, x and y are as defined herein. Compounds according to Formula I are pharmacologically effective as potassium channel inhibitors, in particular inhibitors of the acetylcholine operated inward rectifying potassium channel current (i.e. IKACh blockers), and are... Agent: Astrazeneca Ab

20120142662 - Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142661 - Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel oxime azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142666 - Azetidine 2-carboxamide derivatives which modulate the cb2 receptor: Compounds of the formula (I), (II) and (III) which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Boehringer Ingelheim International Gmbh

20120142668 - Cathepsin c inhibitors: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.... Agent:

20120142663 - Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142664 - Novel benzyl azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel benzyl azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142667 - Pyrimidine derivatives as zap-70 inhibitors: wherein R1 to R5, X and X1 to X3 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including... Agent:

20120142665 - Triazolopyridine compounds: e

20120142660 - Aminopyrimidines useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent: Vertex Pharmaceuticals Incorporated

20120142669 - N-(amino-heteroaryl)-1h-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy: e

20120142670 - N-(amino-heteroaryl)-1h-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy:

20120142671 - Benzamides and nicotinamides as syk modulators: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods... Agent: Portola Pharmaceuticals, Inc.

20120142672 - Heterocyclic compound and use thereof: e

20120142673 - Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors:

20120142674 - N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor:

20120142675 - Methods for treating diseases of the retina: Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a compound selected from the group consisting of olanzapine, certain of its metabolites, clozapine, and n-desmethyl clozapine.... Agent: Allergan, Inc.

20120142676 - Oxathiazine and dithiine oxides as inhibitors of sulfhydryl-dependent biomolecules: Novel derivatives of dihydro-1,4,2-oxathiazine and dihydro-1,4-dithiine oxides, more particularly, novel derivatives of dihydro-1,4,2-oxathiazine and dihydro-1,4-dithiine oxides that target cysteine residues of biomolecules of pharmacological importance are provided as pharmaceutically useful compounds, for example, as anticancer, antiinfectious, antigastric acid secretion, antiosteoporosic, and antiinflammatory agents.... Agent:

20120142677 - Pyrrolidine compounds which modulate the cb2 receptor: Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. (I)... Agent: Boehringer Ingelheim International Gmbh

20120142678 - Novel compound useful for the treatment of degenerative and inflammatory diseases: A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection,... Agent: Galapagos Nv

20120142679 - Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof: The invention relates to the novel materials of formula (I), where R1 is an optionally substituted L-aryl or -heteroaryl, such that L is: an alkyl or CO, or LX, with Lbeing an alkyl and X being O or S; R2 is H or an alkyl; R3 is an alkyl optionally... Agent: Sanofi

20120142680 - Heteroalkyl linked pyrimidine derivatives: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be... Agent: S*bio Pte Ltd.

20120142681 - Heterocyclic hydrazone compounds: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use... Agent: Novartis Ag

20120142682 - Antivirulence compounds inhibiting bacterial mono-adp-ribosyltransferase toxins: Compounds that inhibit bacterial virulence factors from the mono-ADP-ribosyltransferase (mART) family of toxins have been identified that are not toxic to cells or the producing bacterial pathogen. These compounds have great potential as antivirulence agents for treating many bacterial infections and disease states.... Agent: University Of Guelph

20120142684 - Compounds and methods for skin repair: The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles.... Agent: Allergan, Inc.

20120142683 - Pyrimidine substituted purine compounds as kinase (s) inhibitors: The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure (I) or a pharmaceutically acceptable salt thereof... Agent: S*bio Pte Ltd.

20120142685 - Organic compounds: The present invention provides a compound formula I: (formula I) said compound is inhibitor of selective subset of kinases belonging to the AGC or calmodulin kinase family, such as for example MARK1/2/3, PKD-1/2/3, PKN-1/2, CDK-9, CaMKII, ROCK-I/II, inhibitors of histone deacetylase (HDAC) phosphorylation, or inhibitors of other kinases. Finally, the... Agent:

20120142686 - Viral polymerase inhibitors: The present invention relates to viral polymerase inhibitors of formula (I), salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections:... Agent: Biota Scientific Management Pty Ltd

20120142687 - Indolecarboxylic acid derivative having pgd2 receptor antagonistic activity: e

20120142688 - Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications: A 1-(substituted aryl)-5-trifluoromethyl-2-(1H)pyridone compounds and pharmaceutical acceptable salts, preparation methods and uses for preparing the drugs for treating fibrosis thereof.... Agent: Central South University

20120142691 - Picolinamide derivatives as ttx-s blockers: The present invention relates to picolinamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these... Agent: Raqualia Pharma Inc.

20120142689 - Serotonin reuptake inhibitors: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for... Agent: Theravance, Inc.

20120142690 - Substituted piperidines: The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders and tumour disorders.... Agent: Bayer Pharma Aktiengesellschaft

20120142692 - Antifolate combinations: The present invention provides combinations of active agents, such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments, the combinations are useful for treating certain conditions, such as rheumatoid arthritis. The invention also provides articles useful to... Agent: Chelsea Therapeutics, Inc.

20120142693 - Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazin: e

20120142694 - Substituted 4-hydroxypyrimidine-5-carboxamides: The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.... Agent: Merck Sharp & Dohme Corp.

20120142695 - Compounds as bradykinin b1 antagonists: e

20120142697 - Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino)phenyl]-benzamide: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt,... Agent:

20120142696 - Substituted indole/indazole-pyrimidinyl compounds: e

20120142698 - Microbiocidal heterocycles: The present invention relates to heterocyclic compounds of formula I which have microbiocidal activity, in particular fungicidal activity as well as methods of using the compounds of formula (I) to control microbes: wherein A is x-C(R10R11)—C(═O)—, x-C(R12R13)—C(═S)—, x-O—C(═O)—, x-O—C(═S)—, x-N(R14)—C(═O)—, x-N(R15)—C(═S)—, x-C(R16R17)—SO2— or X—N═C(R30)—, in each case x indicates the... Agent: Syngenta Crop Protection, LLC

20120142699 - Trazodone and trazodone hydrochloride in purified form: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of... Agent: Aziende Chim. Riun. Ang. Franc. A.c.r.a.f. S.p.a.

20120142700 - Microbiocidal heterocycles: The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity, as well as methods of using the compounds of formula (I) to control microbes.... Agent: Syngenta Crop Protection, LLC

20120142701 - Compounds and methods for the treatment of proliferative diseases: Cell-based and cell-free assays are disclosed that detect compounds that promote aggregation of proteins, glycoproteins, and protein-nucleic acid complexes. Also disclosed are pharmaceutical formulations useful for treating or preventing viral infections, bacterial infections, cancer, and diseases involving hyper-proliferative cells.... Agent: The University Of Hong Kong

20120142702 - Integrin-linked kinase inhibitors: l

20120142703 - New combination therapy in treatment of oncological and fibrotic diseases: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.... Agent: Boehringer Ingelheim International Gmbh

20120142704 - Pharmaceutical solution of cetirizine hydrochloride: A pharmaceutical solution comprising cetirizine hydrochloride, an alcohol compound with less than 3 carbon atoms, a preservative and urea is disclosed. The cetirizine hydrochloride is in racemic form or in levo form.... Agent: Lun Better Pharmaceutical Co., Ltd

20120142705 - Isatin and oxindole compounds: p

20120142706 - Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment: Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.... Agent:

20120142710 - Ketolide compounds having antimicrobial activity: The invention relates to ketolide compound of Formula-I and the pharmaceutically acceptable salts thereof having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compound of invention.... Agent:

20120142707 - Modified c-3 betulinic acid derivatives as hiv maturation inhibitors: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and... Agent: Bristol-myers Squibb Company

20120142708 - Substituted pyridine urea compounds: m

20120142709 - Substituted pyridinone-pyridinyl compounds:

20120142711 - Acid-labile trigger units: The present invention relates to a compound comprising an imine bond as an acid-labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceutical composition comprising said compound.... Agent: Ktb Tumorforschungsgesellschaft Mbh

20120142712 - 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals: The invention relates to 8-[3-amino-piperidin-1-yl]-xanthines and the physiologically acceptable salts thereof, particularly the hydrochlorides thereof.... Agent: Boehringer Ingelheim International Gmbh

20120142713 - Crystalline forms of 6-(1h-imidazol-1-yl)-2-phenylquinazoline: The present invention relates to the solid state of 6-(1H-imidazol-1-yl)-2-phenylquinazoline (I) and therefore to novel crystalline forms of the base and of pharmaceutically acceptable salts and solvates thereof, and also to methods for preparing them, to the respective pharmaceutical formulations and to their therapeutic use. Compound (I) may be obtained... Agent:

20120142714 - Bicyclic compound: e

20120142715 - Polymorph of [4,6-bis(dimethylamino)-2-(4-benzyl)pyrimidin-5-yl]: Provided is a crystalline form of the ethylenediamine salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid, processes for its preparation, pharmaceutical compositions comprising it, and methods of its use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease.... Agent: Boehringer Ingelheim International Gmbh

20120142716 - 4-pyrimidinesulfamide derivative: The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.... Agent:

20120142717 - Compounds: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.... Agent:

20120142719 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods... Agent:

20120142718 - N-17-alkylated prodrugs of opioids: Compounds of formula (II) R1R2R3N+—(C(R1a)(R2a))—Ar—Z—C(O)—Y—(C(R1)(R2))n—N—(R3)(R4)A−II, in which R1R2R3N+, R1a, R2a, Ar, Z, Y, R1, R2, n, R3, R4 and A− have the meanings given in the specification, are useful as prodrugs for opioids (Example 13).... Agent:

20120142720 - Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof: The presently described technology provides phenylethanoic acid, phenylpropanoic acid, phenylpropenoic acid, a salt thereof, a derivative thereof or a combination thereof chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs or compositions of hydrocodone which have a decreased potential for abuse of hydrocodone. The present technology also provides methods... Agent: Kempharm, Inc.

20120142722 - Conjugates of cytotoxic drugs: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. In another aspect of the invention there is provided a conjugate, comprising a cytotoxic agent and a modulating moiety, the... Agent:

20120142721 - Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.... Agent: The Governors Of The University Of Alberta

20120142723 - Ace2 activator compounds and methods of use thereof: The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury.... Agent: University Of Florida Research Foundation, Inc.

20120142724 - Oxazolo[5-4-b]pyridin-5-yl compounds: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.... Agent: Eli Lilly And Company

20120142725 - Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent: The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation Of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided.... Agent: Astellas Ireland Co., Ltd.

20120142727 - Nitrogenous-ring acylguanidine derivative: [Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z1, Z2, Z3, Z4 and Z5 is nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline... Agent:

20120142726 - Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity: The present invention relates to a method of treating a disorder associated with modulation of the FPRL-1 receptor which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a 3,4-dihydroisoquinolin-2(1H)-yl-3-phenylurea derivative.... Agent: Allergan, Inc.

20120142728 - Chemical compound and its use: The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the... Agent: Bayer Pharma Aktiengesellschaft

20120142729 - Kat ll inhibitors: The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.... Agent: Pfizer Inc.

20120142730 - Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients: The subject invention provides methods for reducing or inhibiting progression of the level of fatigue in a multiple sclerosis human patient, for improving or inhibiting deterioration of the functional status of a multiple sclerosis human patient, and for improving or inhibiting deterioration of the general health of a multiple sclerosis... Agent:

20120142731 - Methods of inhibiting viral infection: wherein each X is independently H or an electrodonating group, each Y is independently H, alkyl of 1-4 carbon atoms, hydroxy, alkoxy or methylene and wherein Substituent Z is a di-or-tri akly amino, or alkyl di or tri amino, optionally substituted with a halogen moiety. This family of compounds, designated... Agent: Functional Genetics, Inc.

20120142733 - 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of ccr2: wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method... Agent:

20120142732 - Heteroaryls and uses thereof: e

20120142735 - Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]- 1h-indol-3-yl]-methanones: or a pharmaceutically acceptable salt of said compound, or a pharmaceutical composition comprising the compound of formula I and a pharmaceutically acceptable carrier. The invention is also directed to the use of a compound of formula I as an inhibitor of tryptase and for treating a patient suffering from, or... Agent: Sanofi

20120142734 - Methods for treating tumors with thalidomide: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.... Agent:

20120142736 - Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142738 - Pharmaceutical composition for treating dermatological autoimmune diseases: There is proposed a pharmaceutical composition for treating dermatological autoimmune diseases, comprising a proton pump inhibitor.... Agent:

20120142737 - Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination: A method for treating gastric acid disorders with a non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal and a carbonate salt of a Group IA metal; and a pharmaceutical composition of a non-enteric coated proton pump inhibitor in a... Agent:

20120142739 - Novel oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142740 - Novel alkene derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel alkene derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142742 - Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.... Agent: Bayer Healthercare LLC

20120142741 - Pharmaceutical compositions for the treatment of cancer: This invention relates to novel pharmaceutical compositions comprising a solid dispersion of the compound of Formula I below, to processes for preparing these novel pharmaceutical compositions and to their use for treating hyper-proliferative disorders, such as cancer, either as a sole agent or in combination with other therapies. Formula I... Agent:

20120142743 - Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate: New polymorphic forms of flupirtine maleate are described.... Agent: Pliva Hrvatska D.o.o.

20120142744 - Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives: The present invention relates to novel combinations of fatty acid derivatives and pyridine carboxy derivatives, including fatty acid esters with glycerol and 3-carboxy pyridine derivates such as niacinamide. Such combinations have surprisingly shown antiviral and anti-microbial activity and the use for the treatment of inflammatory conditions and infections is disclosed... Agent: Astion Dermatology A/s

20120142745 - Novel phenyl oxadiazole derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to novel phenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20120142746 - Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure: The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising a ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, of enantiomers thereof, of tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.... Agent: Allergan, Inc.

20120142747 - Compositions and methods for delivering clonidine to a target tissue site: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release clonidine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e.... Agent: Warsaw Orthopedic, Inc.

20120142748 - Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.... Agent: Glenmark Pharmaceuticals S.a.

20120142749 - Solid salt forms of a pyrrole substituted 2-indolinone: The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1, 2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pirrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders.... Agent: Pfizer Inc.

20120142750 - Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells: The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.... Agent: Medical College Of Georgia Research Institute, Inc

20120142751 - Methods for the production of biliverdin: The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.... Agent: The United States Of America, As Represented By The Secretary, Department Of

20120142752 - Hiv protease inhibitors: Compounds of Formula (I) are disclosed; wherein XA, k, A, B, R3A, R3B, R4 and R5 are defined herein. The compounds of Formula (I) are HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment,... Agent: Merck Sharp & Dohme Corp.

20120142766 - Substituted 1,3-dioxanes and their uses: The present invention relates to compounds containing 1,3-dioxane moiety, pharmaceutical compositions thereof, and the use of the compounds and compositions for the modulation of thromboxane A2 or a peroxisome proliferator-activated receptor. The compounds, analogs, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions can be used in the treatment and prevention... Agent: Evolva Sa

20120142767 - Pine pco ester cosmetic composition: The invention relates to a cosmetic composition for repairing and optionally preventing the effects of skin ageing, based on an extract of Pinus pinaster bark, the procyanidolic oligomers (PCOs) of which are esterified with a fatty acid. These compositions are particularly useful for increasing collagen synthesis, for soothing the skin,... Agent: Action Pin

20120142768 - Formulations including amiodarone and salts thereof and methods of their manufacture and use: The invention encompasses ready to administer liquid formulations including amiodarone and a substituted cyclodextrin. The invention also encompasses methods of making the liquid formulations to provide acceptable concentrations of amiodarone suitable for parenteral administration. The liquid formulations of the invention are formulations included, for example, in a ready to use... Agent: Baxter International Inc.

20120142769 - Methods for treating or preventing fatigue: The present invention relates to the use of compounds of the invention for treatment and/or prevention of fatigue, including fatigue associated with diseases or treatments.... Agent:

20120142770 - Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes: The present invention provides pharmaceutical compositions of an HDAC inhibitor and a chelatable metal compound. In one embodiment, the invention provides a method of treating cancer and alleviating the side effects of the HDAC inhibitor by administering the pharmaceutical composition. In another embodiment, the present invention also provides pharmaceutical compositions... Agent: Merck Sharp & Dohme Corp

20120142771 - Biphenylacetamide derivative: The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, C1-6 alkyl, C1-6 alkoxy substituted with fluorine atom, and others; R4 and R5 are independently selected... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120142772 - Benzo lipoxin analogues: Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.... Agent: University Of Southern California

20120142773 - Use of pufas for treating skin inflammation: n

20120142774 - Emulsifying preparation: An emulsifying preparation for an oil-soluble component, which is sensorily superior when applied to an aqueous phase, can maintain stability for a long time, and imposes less restriction for formulation or production is provided. The emulsifying preparation of the present invention contains (A) an oil phase component containing an oil-soluble... Agent: Ajinomoto Co. Inc

20120142775 - Treatment of neurodegenerative conditions: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic... Agent: Btg International Limited

20120142776 - Methods and compositions for inducing physiological hypertrophy: Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition.... Agent:

20120142777 - Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use: There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an α-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed.... Agent: Newron Pharmaceuticals S.p.a.

20120142778 - Microbiological method for synthesizing cinnamoyl amide derivatives of amino acids: Method for the microbiological production of cinnamoyl amide derivatives of amino acids, certain products that result therefrom and uses thereof, especially as antioxidants.... Agent:

20120142779 - Stable injectable compositions: This invention relates to a stable parenteral aqueous solutions comprising either (a) diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or (b) an inclusion complex of diclofenac or a pharmaceutically acceptable diclofenac salt and a cyclodextrin, or a mixture of (a) and (b), which are suitable for intramuscular... Agent:

20120142780 - Use of 2,5-dihydroxybenzenesulfonic acid in the manufacturing of medicines, applicable to the treatment of angiodependent diseases: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present... Agent: Action Medicines

20120142781 - Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Magnesium Diagnostics Inc.

20120142783 - Enhanced bimatoprost ophthalmic solution: i

20120142782 - Enhanced cimatoprost ophthalmic solution:

20120142784 - Lysine-specific demethylase 1(lsd1) is a biomarker for breast cancer: The present invention relates to novel biomarker for breast cancer, namely LSD1 and its application in inter alia the diagnosis of breast cancer. Furthermore, the present invention discloses a method of determining the LSD1 protein amount and the effect of LSD1 inhibitors on cancer cells selected from breast cancer, lung... Agent:

20120142785 - Methods for treating alzheimer's disease: Alzheimer's disease is treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.... Agent: Cognition Pharmaceuticals LLC

20120142786 - Oregano extract for alertness: Oregano extract can act as a stimulant, yet it does not interfere with sleep patterns or induce nervousness the way many stimulants such as caffeine can. It also has the benefits of promoting improved vigilance, improving attention and ability to focus on a task, and improving general alertness.... Agent:

20120142787 - Aldehyde-functionalized polysaccharides: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or... Agent: E. I. Du Pont De Nemours And Company

20120142788 - Cosmetic preparation containing acyl arginates: Cosmetic or dermatological emulsions with a content of one or more acyl arginates of the formula, wherein R can have values from 5 through 17 and preferably represents an unbranched alkyl chain of 11 C atoms (=lauroyl arginate).... Agent: Beiersdorf Ag

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.0927 seconds

PATENT INFO